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ABSTRACT

My doctoral studies focused on studying FA metabolism in the deadly protozoan
parasite T. brucei. In my dissertation, I addressed various aspects of the
regulation of TbACC, which catalyzes the first committed step in FA synthesis. In
the second chapter, I hypothesized that TbACC is regulated in response to
environmental lipids. I examined changes in TbACC RNA, protein abundance,
and enzymatic activity in response to different levels of environmental lipids in
both BF and PF cells. I also delineated the mechanisms by which TbACC
expression and activity is regulated by phosphorylation in response to altered
lipid environments. In the third chapter, which has been published, we tested the
effects of a compound in green tea extract known as epigallocatechin gallate
(EGCG), on growth of T. brucei, and on TbACC activity and phosphorylation.
EGCG is a known inducer of AMPK, which phosphorylates ACC in other
organisms. In the fourth chapter, I demonstrated that TbACC in PF is also
regulated by various allosteric regulators. I also showed that TbACC might form
oligomers. Together these studies have given an insight on the ability of T. brucei
to regulate its FA synthesis and the role this pathway may play in the survival of
this deadly parasite in its hosts. This knowledge may be exploited in the future to
find a better cure for Trypanosomiasis.
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CHAPTER ONE
LITERATURE REVIEW

INTRODUCTION
Trypanosoma brucei, an early branching protozoan belonging to the family
Trypanosomatidae is a 15-30 µm long, highly motile organism powered by a
single flagellum. At the base of the flagellum is the kinetoplast, which is the highly
condensed genome of the single tubular mitochondrion and marks T. brucei as a
member of the class of Kinetoplastida, which contains both free-living and
parasitic species. T. brucei species causes fatal disease in humans and animals
and are transmitted by an insect vector, the tsetse fly (Glossina species).
Trypanosomiasis affects people and animals living in the ~6.2 million
square miles of sub-Saharan Africa (FAO, Food and Agricultural Organization of
the United Nations, 2007). The World Health Organization (WHO) indicates that
between 1998 and 2004 there were an estimated 50,000 – 70,000 cases
annually of human African trypanosomiasis (HAT) (WHO, 2010). More recently
sustained control efforts have reduced the number of reported HAT cases, with
6,743 and 7,197 cases reported in 2011 and 2012, respectively. However, HAT
remains a major public health concern in 36 countries (Simmaro et al., 2009),
particularly in some regions (Democratic Republic of Congo, Angola, and South
Sudan), where the infection rate is especially high, exceeding malaria or HIV/
AIDS as a cause of death (WHO, 2010).
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Three different T. brucei sub-species affect sub-Saharan Africa: T. b.
brucei, T. b. gambiense and T. b. rhodesiense. T. b. brucei causes disease in
domestic and wild animals but not humans. T. b. brucei’s inability to infect
humans can be attributed to its susceptibility to human trypanolytic factor (TLF),
which is a type of high density lipoprotein particle in human serum. Endocytosis
of TLF by T. b. brucei causes lysis of the parasites (Wheeler, 2010). Cattle and
other mammals lack TLF in their serum, which makes them susceptible to
infection by T. b. brucei. However, T. b. rhodesiense and T. b. gambiense are
resistant to TLF and therefore can successfully infect humans. T. b. gambiense
causes endemic disease in central and west Africa, while T. b. rhodesiense
affects east and south Africa (Brun et al., 2010) (Fig. 1.1). The Nile Rift Valley is
responsible for the strict geographical distribution that physically separates the
insect vectors bearing these two human infective strains. However, in northwest
Uganda these strains do overlap due to the occurrence of both strain-bearing
vectors.

AFRICAN TRYPANOSOMIASIS
African Sleeping Sickness
HAT, also commonly known as African sleeping sickness, differs depending on
which sub-species causes infection. T. b. gambiense causes a chronic infection
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Figure 1.1: Geographic distribution of T. brucei. T. b gambiense causes endemic disease in
central and west Africa, whereas T. b. rhodesiense affects east and south Africa. Both strains are
geographically separated by the physical separation of their corresponding insect vectors by the
Great Rift Valley (WHO, 1999).

with death occurring after ~3 years, while T. b. rhodesiense causes an acute
infection resulting in death in 2-3 months (Brun et al., 2010). There are reports
that demonstrate in some untreated patients that T. b. gambiense infection is not
always fatal. However, very little is known about the frequency of self-cure or
latent asymptomatic infections (Jamonneau et al., 2012).
There are two distinct clinical stages of HAT:, the haemolymphatic stage
(stage I) and the meningo-encephalitic stage (stage II). In stage I, the parasite is
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limited to the bloodstream and lymph nodes. This results in non-specific
symptoms such as intermittent fever, headache, lymphoadenopathy (swollen
lymph nodes), pruritus (itching), joint pains, and to lesser extent
hepatosplenomegaly (enlarged liver or spleen). If infection is not treated in stage
I, then the disease progresses to stage II after several weeks, months, or even
years. In stage II, the parasite crosses the blood-brain barrier and invades the
cerebrospinal fluid. Stage II symptoms include dramatic neurological and
psychiatric symptoms, including sleep disturbances, tremor, fasciculation
(involuntary muscle contraction and relaxation), general motor weakness, limb
paralysis, hemiparesis (weakness on one side of the body), akinesia (inability to
move around), and abnormal movements, such as dikinesia (slight tremor of the
hands) and orchoreo-athetosis (occurrence of involuntary movements).
Hallucinations are also reported in rare cases. Without treatment, patients with
stage II HAT slip into a coma and die (Brun et al., 2010).

Nagana
Cattle and other livestock lack TLF, and are thus susceptible to T. b.
brucei, which causes animal trypanosomiasis, also known as nagana
(Baumgärtner, et al., 2008). Nagana is a wasting disease of livestock and
undermines the establishment of an efficient agricultural system in sub-Saharan
Africa, resulting in estimated economic losses of ~$4.5 billion dollars annually
(FAO, Food and Agricultural Organization of the United Nations, 2007).
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The primary clinical signs of nagana are intermittent fever, anemia, and
weight loss. Cattle usually have a chronic infection, lasting a few weeks to
several months depending upon the virulence. This infection may result in high
mortality, especially if there is poor nutrition or other stress factors present. Some
African cattle breeds are considerably more resistant to African trypanosomiasis.
Susceptibility studies have shown these cattle have existed in the regions for
over 5,000 years. The mechanism of trypano-tolerance has been demonstrated
to have a genetic basis (Moulton and Sollod, 1976; Murray et al., 1984).

Diagnosis
The CATT (Card Agglutination Test for Trypanosomiasis) is the most rapid
serological test available for T. b. gambiense. Various patient samples such as
serum, capillary blood from finger prick, and blood from impregnated filter papers
are used with 87-98% sensitivity and 93-95% specificity (Noireau et al., 1988;
WHO, 1998; Jamonneau et al., 2000; and Truc and Cuny, 2000). The CATT test
relies on the presence of antibodies in patient sera to commonly occurring
variants of T. b. gambiense surface proteins known as variant surface
glycoproteins (VSGs). However, there is no serological test presently available
for T. b. rhodesiense. The CATT is not a very effective diagnostic tool for T. b.
rhodesiense as there are few commonly occurring VSGs that could be used.
Hence, microscopic analysis of blood and/or lymph node aspirate is widely used
for direct pathological confirmation of T. b. rhodesiense infection, as well as to
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confirm T. b. gambiense infection. More advance diagnostics such as
immunofluorescence or enzyme-linked immunosorbent assays are generally
used in non-endemic countries (WHO, 1998) (Lejon et al., 1998). PCR-based
diagnostics have the potential to provide a useful and sensitive method, though
these tests need further validation and standardization (Chappuis et al., 2005).
Sensitive methods such as loop-mediated isothermal amplification (LAMP),
which relies on amplification of a multicopy transposon-like sequence for
detection of T. brucei, has promise as it can be used with specific primers for
sub-species determination (Njiru et al., 2008). However the biggest drawback is
that these molecular diagnostic techniques are expensive, time-consuming, rely
on more advanced infrastructure, and require highly trained personnel.

Treatment
Current treatment of HAT focuses on preventive strategies and
chemotherapy. Preventive strategies are aimed at vector control, such as
trapping, habitat destruction, and insecticide treatment. These methods can be
cost effective, but are labor and time-intensive. The treatment of HAT depends
on the stage of disease (I vs. II) and on the infective species (gambiense vs.
rhodesiense) (WHO, 2010).
Stage I drugs
Pentamidine is used to treat stage I T. b. gambiense infection. It is
administered intramuscularly or as a 2 h intravenous (IV) infusion every 24 hours
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for 7 days. Pentamidine is well tolerated in patients and no resistance has been
reported in the field. Some of the adverse reactions include hypoglycemia,
injection site pain, diarrhea, and nausea. Pentamidine is transported into T.
brucei by at least three known transporters. Pentamidine selectively binds to the
minor groove of kinetoplast DNA, leaving the nuclear DNA unaffected. This
promotes the cleavage of kinetoplast minicircle DNA, eventually leading to
dyskinetoplastic cells (Barret et al., 2007). Pentamidine is also a reversible
inhibitor of S-adenosylmethionine decarboxylase, an enzyme in the polyamine
biosynthetic pathway, but this is unlikely to be the primary mechanism of action
(Barret et al., 2007 and Wang, 1995).
Suramin is used to treat stage I T. b. rhodesiense infection. The dosing
regimen is IV injections every 7th day for a month, with escalating dosage over
the course of treatment (WHO 1986). Severe allergic reactions are often
reported, and other side effects include albuminuria and hematuria (protein and
blood in urine, respectively) and peripheral neuropathy. Suramin binds to T.
brucei LDL receptors and thus, is rapidly endocytosed by the parasite. Suramin
inhibits enzymes in the glycolytic and pentose phosphate pathways, resulting in
rapid lysis of the parasite as the bloodstream form relies exclusively on
glycolysis. Suramin also affects other enzymes such as thymidine kinase and
dihydrofolate reductase (Wang, 1995).
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Stage II drugs
Neither suramin nor pentamidine can be used for stage II T. brucei
infection, as these drugs cannot penetrate the blood-brain barrier (Nok et al.,
2003). Until 1990, melarsoprol was the only drug available for the treatment of
stage II HAT. It is given either as a series of 2-3 daily IV infusions for over a
month or as single daily injections for 10 days (Chappuis, 2007). Like suramin,
the mode of action of melarsoprol is not clear, but it is known to inhibit glycolytic
enzymes such as pyruvate kinase, phosphofructokinase, and fructose-2,6bisphosphatase (Wang et al., 1995). Melarsoprol is also known to affect the
redox balance of T. brucei by forming adducts with trypanothione (N1,N8bisglutathionyl spermidine), a metabolite unique to trypanosomes (Wang et al.,
1995; Fairlamb et al., 1985; Fairlamb et al., 1989).
Melarsoprol, being an arsenic derivative, is very toxic to humans. Ten
percent of patients administered this drug suffer from reactive arsenic-induced
encephalopathy often followed by pulmonary edema and death within 48 h. Other
common side effects include skin reactions such as pruritus (itching) and
maculopapular eruptions (rash), peripheral motoric palsy (loss of movement),
sensorial paraesthesia (loss of senses), neuropathies, and thrombophlebitis (vein
inflammation). Highly insoluble in water, melarsoprol is dissolved in glycol, which
also makes it very painful to administer (described as “fire in the veins”) and
destroys veins after several administrations (Chappuis, 2007; Priotto et al.,
2006).
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Difluoromethylornithine (DFMO), or eflornithine, is a more recent drug to
treat stage II HAT, but it is only effective against T. b. gambiense infections. The
drug is administered by IV infusion every 6 h for 14 days (Priotto et al., 2006;
Checchi et al., 2007). Side effects of eflornithine treatment include bone marrow
suppression, gastrointestinal symptoms, and convulsions, all of which subside
upon completion of treatment (Chappuis et al., 2004). Eflornithine is an enzymeactivated irreversible inhibitor of ornithine decarboxylase (ODC), the initial
enzyme in the polyamine synthetic pathway (Bacchi et al., 1980). The major
downsides of this drug are its cost, the complexity and duration of treatment, and
its limited availability (Chappuis et al., 2004).
Nifurtimox Eflornithine Combination Therapy (NECT), introduced in 2009,
is the latest approach to treat stage II HAT. Nifurtimox is a registered drug for T.
cruzi treatment and initial studies showed that the combination of eflornithine and
nifurtimox was far superior to either eflornithine or melarsoprol and resulted in far
less toxicity (Priotto et al., 2007). The use of NECT also reduced the treatment
regimen from 14 days to 7 days with a 94% cure rate. NECT has an additional
benefit of easier administration, resulting in a reduction in staff and logistic
resources. Combining two drugs also may reduce the possibility of the
development of drug resistance. However, NECT is not effective for T. b.
rhodesiense treatment (Kansiime et al., 2009).
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PARASITE LIFE CYCLE
T. brucei is transmitted as metacyclic trypomastigotes through the bite of
the infected tsetse fly. After inoculation into the mammalian host, the parasites
proliferate at the infection site, which can cause an inflamed nodule or ulcer
(Tatibouet et al., 1982), though the ulcers are rare with T. b. gambiense infection.
Once in the bloodstream, T. brucei transforms into bloodstream form (BF)
trypomastigotes that undergo rapid binary fission and populate the blood and
lymph. Later during infection, BFs transform into non-dividing short stumpy
forms, which are primed for return to the tsetse fly host. When a tsetse fly feeds
on an infected mammal, the fly takes up the short stumpy forms with the blood
meal (Fig. 1.2).
In the fly midgut, T. brucei transforms into procyclic form trypomastigotes
(PFs), which also multiply by binary fission. The PFs then exit the midgut,
traverse through the hemolymph, and migrate into the salivary glands, where
they transform into epimastigotes. These epimastigotes undergo meiosis and
sexual reproduction before undergoing a final transformation into metacyclic
forms (Peacock et al., 2011), which are ready for transmission to another
mammalian host (Matthews, 2005; Fenn et al., 2007; CDC, 2012).
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Figure 1.2: T. brucei life cycle. T. brucei cycles between its mammalian host and insect vector,
the tsetse fly. Figure is modified from (Lee et al., 2007).

PARASITE SURVIVAL STRATEGIES IN THE HOST
Parasite surface coats
In both the insect and mammalian stages, T. brucei expresses surface
coat proteins that are important for its survival. The PF surface coat is composed
of 106 copies of procyclin (Richardson et al., 1988; Roditi et al., 1989), a
glycosylphosphatidylinositol (GPI)-anchored protein containing characteristic
amino acid repeats at the C terminus: either Glu-Pro repeats (EP procyclin) or
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Glu-Pro-Glu-Glu-Thr repeats (GPEET procyclin). The procyclin GPI anchor
contains one C16:0 (palmitate) and one C18:0 (stearate) fatty acid as the lipid
moiety (Butikofer et al., 1997). Procyclins are predicted to play a role in
protecting these parasites against proteolytic degradation in the tsetse fly midgut
(Acosta-Serrano et al., 2001).
In the mammalian bloodstream, T. brucei is fully exposed to the immune
system, but has multiple strategies to evade the host’s immune responses. The
BF surface coat protein VSG plays a key role in the parasite’s ability to evade the
mammalian immune system. VSGs are also GPI-anchored to the plasma
membrane, and the lipid moiety consists of two C14:0 fatty acids (myristate).
VSGs are highly immunogenic and form a dense coat around the parasite with
107 copies per cell. The VSG coat protects the invariant surface antigens from
immune recognition and stimulates a strong antibody response. Periodic
shedding of VSG coat provides protection from complement-mediated lysis
(Tachado and Schofield, 1994; Taylor and Rudenko, 2006).
The T. brucei genome possesses >1500 different VSG genes and ~20
different VSG expression sites (Barry et al., 2005; Berriman et al., 2005; Marcello
et al., 2007). Only one VSG is expressed at a time, a process tightly regulated by
an allelic exclusion mechanism. At any one time, parasites expressing the
dominant VSG coat are lysed and killed by the host immune system, and a
subset of the parasite’s population switches its coat to a different VSG before
being killed by the immune system (Turner and Barry, 1989). This periodic VSG
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switching forces the immune system to mount successive waves of specific
antibodies against the distinct VSGs (Borst et al., 2002). Hence the immune
system can never completely destroy the parasite and the parasite population
persists in the host, ultimately causing severe symptoms and death of the host if
untreated.
Evasion of complement mediated lysis
A ~10-fold higher endocytosis rate is observed in BFs compared to PFs
(Natesan et al., 2007; Field and Carrington, 2009). This upregulation of
endocytosis clears antibodies bound to the parasite surface, thereby evading the
antibody-mediated complement cascade and resulting death by cell lysis.
Upregulation of both fluid phase endocytosis and receptor-mediated endocytosis
is associated with the clearance of antibodies and complement from the surface
(Barry, 1979; Ferrante and Allison, 1983; Pal et al., 2003; Engstler et al., 2007).
Upregulation of fluid phase endocytosis is responsible for the high general
membrane turnover rate observed in BFs (i.e. complete VSG turnover occurs in
~12 minutes) (Engstler et al., 2004), whereas upregulation of receptor-mediated
endocytosis is responsible for clearing surface-bound antibodies and
complement from the parasite surface via VSG recycling (Kabiri and Steverding,
2000; Chung et al., 2004; Field and Carrington, 2009). VSG bound to antibodies
and complement are internalized via the flagellar pocket into a VSG recycling
endosome, which contains proteases that selectively degrade and inactivate the
antibodies and complement. The VSG is then recycled back to the surface.
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Modulation of host immunity
Trypanosomes are sensitive to reactive oxygen and nitrogen species, a
common immune killing mechanism. In the bloodstream, T. brucei triggers a
cascade of immune reactions modulated for the benefit of the parasite (Shi et al.,
2004; Pan et al., 2006). T. brucei activates polyclonal B cell expansion, which
induces the production of IgM antibodies. The parasites are opsonized by IgM
(and IgG) antibodies, which activates macrophage recruitment and leads to the
production of inflammatory cytokines. These inflammatory cytokines then downregulate the production of reactive oxygen and nitrogen species. At the same
time, T. brucei suppresses the development and function of T lymphocytes,
which results in an overall immune suppression (Barrett et al., 2003). T. brucei
also secretes immunomodulatory molecules (Trypanokines) that mimic the
activities of host cytokines (Vaidya et al., 1997) and are capable of triggering
immune responses that are not required for elimination of the parasite itself
(Sharafeldin, 1999) but favors survival and persistence of T. brucei and
establishment of later stages of infection (Hamadien et al., 1999). These
immunomodulatory tactics provide the parasite additional mechanisms to evade
the host immune system (Lucas et al., 1994).

HOST MICROENVIRONMENTS
In the different stages of its life cycle, T. brucei encounters a number of
distinct microenvironments. In the insect, the parasite encounters the tsetse
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midgut, ectoperitrophic space, and salivary glands; while in the mammal, the
parasite encounters the blood, lymph, and cerebrospinal fluid (Fig. 1.3). These
environmental niches differ in their nutrient composition, including lipids. For
example, when T. brucei leaves the bloodstream and crosses the blood-brain
barrier, it experiences a dramatic ~300-fold drop in environmental lipids (Roheim
et al., 1979).

Figure 1.3: Host microenvironments. T. brucei encounters different microenvironmental niches
in its tsetse fly and mammalian hosts, which differ in their nutrient composition including fatty
acids.

Fatty acids (FAs) are the simplest lipids and they play a major role in T.
brucei. Not only are FAs structural components of membranes, but they are also
cell signaling molecules and play a vital role in protein localization via membrane
anchors. In particular, FAs are key constituents of GPI-anchors that localize
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surface proteins like VSG and Procyclin. The high density of these GPI-anchored
coat proteins creates a high demand for FAs in T. brucei.
T. brucei can effectively take FAs from the host or synthesize their own to
satisfy its fatty acid requirements. If FAs in the host microenvironment become
limiting, then T. brucei must rely on FA synthesis. Synthesis of FAs requires
more energy than uptake, thus T. brucei must have the ability to efficiently
regulate de novo FA synthesis to meet its changing nutrient demands (Fig. 1.4).
Earlier studies in our lab demonstrated that a growth defect was observed in PFs
when FA synthesis was knocked down in cells grown in low lipid conditions
(Vigueira et al., 2011). Knock down of FA synthesis also reduced virulence in a
mouse model of infection (Vigueira et al., 2011). A high demand for FAs is also
created by the need to maintain a high membrane turnover required to avoid
antibody-mediated complement lysis (McKnight, 2012).
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Figure 1.4: Fatty acid synthesis vs. uptake. T. brucei can effectively take up FAs when
environmental lipids are available. However, under conditions of limited external lipids, T. brucei
synthesizes FAs by converting acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC).
The malonyl-CoA is then used by the ELO pathway for FA synthesis.

FATTY ACID UPTAKE
One mode of lipid uptake in various systems is the endocytosis of
lipoproteins. Lipoproteins have a polar surface layer made up of phospholipids,
apolipoproteins and cholesterol; and a non-polar inner core comprised of
triglycerides, cholesterol, and cholesterol esters (Wasan et al., 2008). After
internalization, the lipoproteins are transported to lysosomes where they are
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degraded and the lipids are liberated. In addition, lipoproteins are also acquired
directly from donor lipoprotein particles without being transported to lysosomes
(Engelmann and Weidmann, 2010).
A second major lipid uptake mechanism involves the direct uptake of
phospholipids and FAs (Glatz et al., 2010). Due to their low aqueous solubility,
these lipids often associate with carrier proteins (typically serum albumin) in the
bloodstream. The internalization of lipids by cells begins with their dissociation
from carrier proteins and partitioning into the outer leaflet of the plasma
membrane bilayer. This is followed by flip-flop movement of the phospholipids
and FAs, which changes the orientation of the polar head group from the outer to
the inner lipid-water interface. This process enables FAs to partition into the cell,
where they become bound or activated, and ultimately incorporated into more
complex lipids. This process follows biphasic kinetics: partitioning into the lipid
bilayer is much faster, and internalization is much slower. The process of lipid
flip-flop, being the slowest step in FA uptake, is considered the rate-limiting step
(Mellors et al., 1989; Kamp et al., 2007a; Kamp et al., 2007b).
The transmembrane protein, CD36, and plasma membrane FA binding
protein (FABP) both facilitate FA diffusion by binding and concentrating FAs on
the membrane surface (Ehehalt et al., 2006). The bound FAs are then more
easily partitioned into the membrane, resulting in a greatly enhanced FA uptake
rate. FA uptake also takes place through lipid rafts associated with caveolae
(Glatz et al., 2010). Caveolin binds FAs with high affinity, but the major role of
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caveolin in FA uptake is likely by providing a docking site for CD36. Supporting
this idea, cholesterol depletion leads to the disassembly of lipid rafts, the
dispersion of CD36 throughout the plasma membrane, and a resulting decrease
in FA uptake (Ehehalt et al., 2006; Glatz et al., 2010). In addition to passive
diffusion, FA uptake is also mediated by a family of FA transport proteins
(FATPs), which are integral membrane proteins responsible for active transport
of FAs into cells (Glatz et al., 2010).
FA uptake can also occur through the action of proteins not associated
with the plasma membrane. FAs must be activated before they can be
metabolized for energy or incorporated into more complex lipid species. FA
activation occurs by the esterification of a FA to Coenzyme A (CoA), mediated by
a family of enzymes called acyl-CoA synthetases (ACS) (Webster, 1963). Failure
to activate FAs can result in free outward passive diffusion and no net uptake.
Activation of the FA to the CoA form makes the FA membrane impermeable, and
thus, retention of FAs internalized by facilitated or passive diffusion is enhanced
by ACSs (Milger et al., 2006).
Fatty acid uptake in T. brucei
Various mechanisms of FA uptake have been described in T. brucei.
Endocytosis of high density and low density lipoproteins by BFs is well described
(Coppens et al., 1995; Green et al., 2003). The lipoprotein scavenger receptor
enhances this process (Green et al., 2003; Thomson et al., 2009). A similar
endocytic mechanism used to take up lipophorin, a family of high density
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lipoproteins in the fly, has been demonstrated in the related trypanosome, T.
rangeli (Folly et al., 2003). Specialized uptake mechanisms for the acquisition of
phospholipids occurs along with lipoprotein uptake in T. brucei. For example, the
coordinated activity of three proteins: phospholipase A1, acyl-CoA ligase, and
lysophosphatidylcholine: acyl-CoA acyltransferase has been confirmed in the
uptake of lysophosphatidylcholine (Bowes et al., 1993).
Little is known about the mechanisms of FA uptake in T. brucei. Proteins
involved in the uptake of FAs have not yet been identified or characterized in
these parasites, though early studies demonstrate that FA uptake occurs with
biphasic kinetics (Voorheis,1980). This kinetic similarity between mammalian and
T. brucei FA uptake suggests the presence of both protein-mediated active
transport and passive diffusion in trypanosomes. The genome of T. brucei
encodes 5 ACSs, four of which have been characterized (Jiang et al., 2000;
Jiang et al., 2001; Jiang et al., 2004).The effect of TbACS knock-down by a PAN
ACS construct was measured by monitoring uptake of a fluorescently tagged
C12:0 FA (BODIPY-C12:0). The uptake of BODIPY-C12:0 was reduced by 34%
in 2 days, 47% in 4 days, and 58% in 6 days upon RNAi induction. However
panRNAi of the TbACSs caused only a small reduction in growth (Vigueira,
2011).
FA synthesis in T. brucei
For many years, only PF T. brucei were thought to posses the ability to
synthesize FAs while BF lacked this capacity (Dixon et al., 1971). However,
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studies showed that both BF and PF can synthesize FAs de novo from a butyrylCoA primer (Morita et al., 2000). Subsequently, the genome project of T. brucei
revealed the absence of a canonical eukaryotic type I FA synthase (Berriman et
al., 2005). Instead, T. brucei possesses a microsomal elongase (ELO) FA
synthesis pathway and mitochondrial type II FA synthesis pathway. T. brucei
relies on the microsomal ELO pathway for the bulk of their FA synthesis (Lee et
al., 2006) in contrast to other eukaryotic organisms, where the ELO pathway is
used for elongation of pre-existing long chain FAs. T. brucei possesses four ELO
genes (ELO1-4) encoding the ketoacyl-CoA synthases of the ELO pathway.
Each of these four ketoacyl-CoA synthases have distinct, but overlapping chainlength specificities: ELO1 (C4:0–C10:0), ELO2 (C10:0–C14:0), and ELO3 (C14–
C18), and ELO4 acts on long chain unsaturated FAs (Lee et al., 2006). The ELO
pathway also comprises two ketoacyl-CoA reductases (KCR), which reduce
ketoacyl-CoA to hydroxylacyl-CoA; a dehydratase that converts hydroxyacyl-CoA
to enoyl-CoA; and an enoyl-CoA reductase that converts enoyl-CoA to an acylCoA two carbons longer than the primer chain. Individual ELOs are not essential
in vivo, likely due to their overlapping substrate specificities. However, RNAi of
the sole enoyl-CoA reductase that acts downstream of all the ELOs suggests that
the ELO pathway as a whole is essential (Lee et al., 2006) (Fig. 1.5).
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Figure 1.5: Enzymatic reactions of FA synthesis pathway in T. brucei. The T. brucei ELO FA
synthesis pathway consists of four reactions: the 2-carbon donor malonyl-CoA is condensed with
a butyryl-CoA primer by ketoacyl-CoA synthase (1), reduced by ketoacyl-CoA reductase (2),
dehydrated by dehydratase (3), and finally reduced by enoyl-CoA reductase (4) to yield a FA
product that 2 carbons longer. The malonyl-CoA is synthesized from acetyl-CoA by acetyl-CoA
carboxylase (ACC). Figure is modified from (Lee et al., 2007).

The mitochondrial type II FA synthesis pathway is composed of one acyl
carrier protein (ACP), one ketoacyl-ACP synthase, three ketoacyl-ACP
reductases, a dehydratase, and two enoyl-ACP reductases (Stephens et al.,
2007; Autio et al., 2008). The major products synthesized by the mitochondrial
type II pathway are C16:0 and C8:0, the latter of which is the precursor for lipoic
acid, a key prosthetic group in several mitochondrial respiratory enzymes.
Mitochondrial FA synthesis is known to account for only ~10% of overall FA
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synthesis in T. brucei, but this pathway is essential in both PFs and BFs to
supply FAs required for lipoic acid synthesis and to locally maintain mitochondrial
membrane composition, respiratory complex functions, and mitochondrial
morphology (Stephens et al., 2007; Guler et al., 2008).
In addition to being found in other trypanosomes such as T. cruzi, ELO
pathways are present in other parasites including Leishmania major, Plasmodium
falciparum, Toxoplasma gondii, and Entamoeba histolytica, though their exact
functions may vary (Lee et al., 2007). The modular structure of the ELO pathway
in trypanosomatids enables differential control of the FA products. This may be
advantageous to allow parasites to adapt to different host environments. For
example, downregulation of ELO3 might be responsible for the observed chainlength preference in BFs to synthesize myristate (C14:0), which is the sole FA
component of the VSG GPI-anchor (Lee et al., 2006; Lee et al., 2007). The
presence of environmental lipids can also lead to the overall up- and
downregulation of the ELO pathway to meet the FA demands of the parasite. For
example, in low lipid conditions the balance shifts towards FA synthesis and
increased ELO pathway activity. In extreme cases, BF will even elongate
myristate, normally the final product of FA synthesis in BFs (Doering et al., 1993;
Lee et al., 2006). The exact mechanisms regulating the ELO and mitochondrial
FA synthesis pathways and the roles they play in T. brucei pathogenesis are
largely unknown.
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ACETYL-COA CARBOXYLASE
Acetyl-CoA carboxylase (ACC) is a key enzyme in the FA synthesis
pathway and catalyzes the first committed step: the conversion of acetyl-CoA to
malonyl-CoA, the 2-carbon donor for FA synthesis (Barber et al., 2005). ACC
uses a biotin prosthetic group to transfer CO2 from bicarbonate to acetyl-CoA in
two half reactions: biotin carboxylation and carboxyl transfer. In bacteria,
archaea, and chloroplasts, ACC is a multi-enzyme complex composed of a biotin
carboxylase (BC) enzyme; a biotin carboxyl carrier protein (BCCP) that carries
the biotin prosthetic group attached to a conserved lysine; and a
carboxyltransferase enzyme (CT) composed of one or two subunits (Fig. 1.6). In
contrast, many eukaryotic ACCs are large multi-domain enzymes composed of
BC and CT domains separated by a BCCP domain (Fig. 1.6).

Figure 1.6: Comparison of ACC protein structure. T.b., T. brucei ACC; S.c., Saccharomyces
cerevisiae ACC; E.C., Escherichia coli ACC.

Known ACC functions
The function of ACC depends on the role of its product, malonyl-CoA. The
majority of metazoans express two different ACC isoforms that differ in their
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functions (Barber et al., 2005): ACC1 (ACCα) initiates FA synthesis in lipogenic
tissues, whereas ACC2 (ACCβ) is expressed in vertebrate oxidative tissues such
as skeletal muscle and heart. ACC2 (ACCβ) is associated with the mitochondria
and plays a role in regulating FA oxidation (Abu-Elheiga et al., 1997; Abu-Elheiga
et al., 2000). Malonyl-CoA synthesized by ACC2 inhibits carnitine
palmitoyltransferase I, part of the machinery that imports FAs into the
mitochondria for oxidation. In tissues such as the liver, both ACC isoforms are
expressed and function coordinately (Abu-Elheiga et al., 1997; Abu-Elheiga et
al., 2001; Mao et al., 2006). In the hypothalamus, ACC also functions as a
component of a malonyl-CoA dependent fuel sensing pathway that regulates
whole body metabolism (Hu et al., 2003; Hu et al., 2005; Wolfgang and Lane,
2006).
In most unicellular organisms, malonyl-CoA formation is the first
committed step in FA synthesis. S. cerevisiae ACC is the best characterized
among unicellular eukaryotes. This organism harbors two ACCs: a cytosolic ACC
that functions in FA synthesis and elongation, and a mitochondrial ACC that
functions in lipoic acid synthesis (Hoja et al., 2004; Hiltunen et al., 2005). Unlike
mammalian ACC2, the S. cerevisiae mitochondrial ACC does not play a role in
regulating FA oxidation, perhaps because FA oxidation occurs in specialized
organelles known as peroxisomes rather than mitochondria (Hiltunen et al.,
2005). Very little is known about ACC in protozoan parasites. The
Apicomplexans Toxoplasma and Plasmodium express two multi-domain ACCs.
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The ACC in the apicoplast (a non-photosynthetic plastid organelle) plays an
essential role in lipoic acid synthesis (Jelenska et al., 2001), however the function
of Apicomplexan cytosolic ACC is not clearly understood (Jelenska et al., 2001;
Gornicki, 2003; Mazumdar et al., 2006). Another Apicomplexan,
Cryptosporidium, expresses only single multidomain ACC, which is located in
cytoplasm (Zhu, 2004; Zhu et al., 2000).
T. brucei ACC
According to the TriTryp database, the T. brucei genome encodes a single
predicted ACC isoform (Tb927.8.7100) (Aslett et al., 2009). Southern blot
analysis confirmed the presence of a single copy gene (Vigueira et al., 2011).
The T. brucei ACC (TbACC) gene is ~6.5 Kb in length and encodes a protein of
2,181 amino acids with a calculated molecular weight 243.9 kD. TbACC shares
the multidomain structure of other eukaryotic ACCs, and multiple sequence
alignments showed that TbACC has a moderate 30% identity to yeast and
human ACCs, and a much higher ~60% identity to other trypanosomatid ACCs
(Vigueira et al., 2011). TbACC is expressed in both BFs and PFs. The
expression of TbACC in PFs is 6-fold higher than in BFs when normalized to
tubulin, which is consistent with a 5-fold higher rate of FA synthesis in PFs
compared to BFs (Morita et al., 2000; Vigueira et al., 2011).
TbACC was predicted to be cytosolic and sub-cellular localization
experiments confirmed this prediction (Vigueira et al., 2011). However,
immunofluorescence microscopy showed that TbACC is localized to a multitude
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of small distinct puncta rather than in a diffuse cytoplasmic distribution (Vigueira
et al., 2011). RNA silencing of TbACC resulted in partial inhibition (50-70%) of
[3H]laurate and [3 H]myristate elongation in PFs. In BFs, TbACC RNAi caused
only a 15% inhibition of [3H]laurate elongation, but completely abolished the
minor elongation of [3 H]myristate. When grown in normal lipid conditions, TbACC
RNAi cells exhibited no growth defect in either PFs or BFs, which could be
attributed to the ability of the parasite to acquire FAs from its environment (i.e.
media). However, when the environmental conditions were changed to low lipid
conditions, TbACC RNAi in PFs reduced growth by 64% (Vigueira et al., 2011).
Though TbACC RNAi had no effect on growth of BFs even in low lipid conditions,
it reduced virulence in mice, nearly doubling the mean time to death when
compared to the uninduced cell line where TbACC was expressed normally.
Regulation of ACC
In mammals, ACC is highly expressed in certain tissues, such as white
and brown fat, liver, and lactating mammary glands, but ACC expression is
inhibited during starvation (Wakil et al., 2009). Three distinct promoters are
known to play a role in controlling the expression of ACC at the transcriptional
level in response to glucose, hormones, and leptins (Hillgartner and Charron,
1997; Mao et al., 2003; Kim et al., 2010). Transcription factors such as sterolregulatory-element-binding protein 1c (SREBP1c), X-receptor, retinoid X
receptor, and peroxisome-proliferator-activated receptors (PPARs) play an
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important role in controlling ACC1 expression (Shimano et al., 1999; Wolfram et
al., 2004; Barber et al., 2005).
Allosteric effectors, such as citrate and other carboxylic acids, are known
to activate mammalian ACC (Vagelos et al., 1963; Lane et al., 1974). Signals
from amino acid metabolism such as glutamate also activate ACC1 (Winz et al.,
2000). Malonyl-CoA, free CoA and FA-CoA esters were also demonstrated to
inhibit ACC1 (Ogiwara et al., 1978; Moule et al., 1992).
Metabolic labeling experiments on liver and fat tissues with [32P]phosphate
demonstrated the presence of at least four hormone-responsive phosphorylation
sites in ACC. Treatment with glucagon leads to the rapid phosphorylation of
ACC, which is an inactivating post-translational modification (Brownsey et al.,
1992; Hardie et al., 1992). Phosphorylation of ACC is mediated by two major
kinases: AMP-dependent protein kinase (AMPK ), and protein kinase A (PKA)
(Hardie et al., 1992).
Many metabolic enzymes are organized in complexes known as
‘metabolons’, where high intracellular protein concentrations favor protein-protein
interactions (Velot et al., 1997). Mammalian and avian ACC activity is regulated
by polymerization: ACC exists as dimeric form but can assemble into a higherorder polymeric form (Kleinschmidt et al., 1969; Mackall et al., 1978; Thampy et
al., 1985; Barber et al., 2005). Allosteric activators such as citrate induces in vitro
polymerization of ACC in chicken liver extracts, where the inactive protomeric
form of the enzyme converts to an active filamentous form composed of 10-20
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protomers (Beaty et al., 1983). In addition, protein inducers like MIG12 can
induce ACC polymerization in mice by lowering the threshold citrate
concentration (Kim et al., 2010). Negative regulators such as malonyl-CoA, ATP,
and Mg2+ causes depolymerization and inactivation of fully polymerized ACC
(Beaty et al., 1983).
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CHAPTER TWO
REGULATION OF T. brucei ACC IN PRESENCE OF ENVIRONMENTAL
LIPIDS

INTRODUCTION
African trypanosomiasis is caused by the parasite Trypanosoma brucei,
which is transmitted by the blood sucking tsetse fly. In mammals, the
bloodstream form (BF) of the parasite exists extracellularly in the bloodstream
and the cerebrospinal fluid. When the tsetse fly feeds on an infected mammal, T.
brucei differentiate into procyclic forms (PF) in the fly midgut. These PFs then
invade the hemolymph, cross the midgut epithelium and enter into the salivary
glands. In the salivary glands, the PFs undergo meiosis and further development
to form an infectious metacyclic form, which is transmissable to a new
mammalian host when the fly takes another blood meal.
T. brucei surface coat proteins play an important role in the survival of the
parasite in its hosts. The T. brucei PF surface coat is composed of ~3 x 106
copies of one of the procyclins, a small family of glycoproteins (Schell and
Overath, 1990; Matthews and Gull, 1994). Procyclins are predicted to play a role
in protecting these parasites against proteolytic degradation in the tsetse fly
midgut (Acosta-Serrano et al., 2001). The T. brucei BF surface coat is composed
of 1 x 107 copies of a single Variant Surface Glycoprotein (VSG) (Tachado and
Schofield, 1994; Taylor and Rudenko, 2006). T. brucei can periodically switch its
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VSG coat to an entirely new antigenic variant thereby allowing the parasite to
avoid destruction by the immune system, a process known as antigenic variation
(Turner and Barry, 1989). Both the procyclin and VSG proteins are GPI-anchored
to the parasite plasma membrane, though their GPI-anchors differ in their fatty
acid (FA) moieties. The procyclin GPI-anchor contains two FAs, a palmitate
(C16:0) esterified to inositol and a stearate (C18:0) esterified to the sn-1 position
of the monoacylglycerol moiety (Field et al., 1991; Butikofer et al., 1997). The
VSG GPI-anchor also contains two FAs, both of which are myristate (C14:0)
(Ferguson and Cross, 1984). Consequently, the need to maintain their lipid
anchored surface coats creates a high demand for FAs. Interestingly, myristate is
not an abundant FA in blood. (Edelstein,1986).
During its life cycle, a host presents T. brucei with different
microenvironments: the blood meal, hemolymph, gut and salivary glands in
tsetse flies; and the bloodstream and cerebrospinal fluid in mammals. In all of
these microenvironments, the parasite encounters differences in nutrient
availability, including FAs. For example, the parasite experiences a dramatic
~400-fold drop in lipid availability when it crosses the blood-brain barrier and
enters the cerebrospinal fluid (Roheim et al., 1979). To satisfy its FA needs, T.
brucei relies on two mechanisms: de novo synthesis of FAs and uptake of
environmental FAs from the host. T. brucei readily takes fatty acids from its host
to supply itself (Mellors and Samad, 1989; Coppens et al., 1995). However,
under conditions of limiting exogenous FAs, T. brucei is unable to rely on uptake
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alone and must synthesize FAs de novo. FA synthesis is functional in both PF
and BF T. brucei (Lee et al., 2006; Stephens et al., 2007).
A canonical eukaryotic cytosolic type 1 pathway does not exist in
trypanosomatids (Aslett et al., 2010). Instead, there are two known FA synthesis
pathways in T. brucei: an elongase pathway localized to the endoplasmic
reticulum that accounts for ~90% of total FA synthesis (Lee et al., 2006) and a
mitochondrial pathway that is responsible for ~10% of total FA synthesis
(Stephens et al., 2007; Guler et al., 2008). Both FA synthesis pathways depend
on a key substrate malonyl-CoA, the 2-carbon chain donor, which is synthesized
from acetyl-CoA by Acetyl-CoA carboxylase (ACC) in what constitutes the first
committed step in FA synthesis (Barber et al., 2005).
T. brucei ACC (TbACC) is 58-66% identical to the ACCs in other
trypanosomatids such as Leishmania and Trypanosoma cruzi (Vigueira et al.,
2011). However, TbACC is only 31-33% identical to human, rat, and
Saccharomyces cerevisiae ACCs (Vigueira et al., 2011). ACC is a member of the
biotin carboxylase family of enzymes, which use a biotin prosthetic group to
transfer a carboxyl group to an acceptor acetyl-CoA (Barber et al., 2005). The
domain identity between the human ACC and TbACC is ~ 48% for the biotin
carboxylase domain, ~30% for the biotin carboxyl carrier protein domain, and
~34% for the carboxyl transferase domain (Vigueira et al., 2011). Earlier studies
demonstrated that RNAi of TbACC in PFs and BFs caused a reduction in FA
elongation (Vigueira et al., 2011). TbACC RNAi also caused a growth defect in
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PFs when environmental lipids were low, and reduced the virulence of BFs in
mouse infection studies (Vigueira et al., 2011).
Because ACC catalyzes the first committed step in FA synthesis, it serves
as a control point for regulating FA synthesis and is known to be highly regulated
by various control mechanisms in other organisms (Brownsey et al., 2006). In
many metazoans, ACC is a component of a fuel-sensing pathway that responds
to the metabolic state of cell (Hu et al., 2003; Hu et al., 2005; Wolfgang and
Lane, 2006). In all systems studied to date, ACC is regulated by phosphorylation.
AMP-activated protein kinase (AMPK) is the best characterized kinase that
phosphorylates ACC, and its function is conserved from yeast to mammals
where it serves as an energy and stress sensor (Winder and Thomson, 2007). In
yeast and mammals, phosphorylation of ACC results in the inhibition of ACC
activity, creating a way to conserve energy during stress (Winder et al., 1997;
Carlson and Winder 1999). Mammalian ACC is phosphorylated on least 6-8
sites, however only 2-3 sites have actually been demonstrated to affect ACC
activity (Tong, 2005). In mammals, the canonical sites for AMPK phosphorylation
are Ser79, Ser1200, and Ser1215, whereas yeast ACC is primarily controlled by
AMPK phosphorylation at Ser1500 (Barber et al., 2005).
ACC likely plays a central role in FA metabolism in T. brucei, however little
is known about ACC in parasitic protozoans and almost nothing is known about
trypanosomatid ACCs and their regulation. In this chapter, I investigated the
hypothesis that T. brucei ACC is regulated in response to environmental lipids. I
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found that ACC activity is increased in low lipid environments and decreased in
high lipid environments. I then delineated the mechanisms by which ACC
expression and activity is regulated in response to altered lipid environments and
found that phosphorylation of TbACC has a negative effect on TbACC activity
and is one of the major post-translational mechanisms regulating TbACC in
response to environmental lipids. Finally, I found that environmental lipid
regulation of TbACC occurs only in PFs and is not observed in BFs.

RESULTS
Effect of environmental lipids on TbACC mRNA levels
To examine the regulation of TbACC at the transcriptional level, we used
qRT-PCR (quantitative reverse transcriptase polymerase chain reaction). Total
mRNA was isolated from lysates prepared from cells grown in low, normal, and
high lipid conditions. qRT-PCR analysis revealed that in both BFs and PFs, there
was no significant difference in TbACC mRNA levels in cells grown in low,
normal, and high lipid conditions (Fig. 2.1 A). There is no significant difference in
TbACC mRNA level between PF and BF when normalized to actin (Fig. 2.1 B).
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A.

Figure 2.1: Environmental lipids do not affect ACC mRNA levels in PF and BF. (A.) BF and
PF T. brucei cells were grown in low, normal, and high lipid conditions to mid-logarithmic stage.
ACC transcript levels were assessed by qRT-PCR and normalized to β-actin as a loading control.
Data shows the mean ± SEM of three independent experiments. (B.) BF and PF ACC RNA levels
normalized to actin as a control.
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Effect of environmental lipids on TbACC protein levels
To investigate regulation of TbACC at the post-translational level, BF and
PF cells were grown in low, normal, and high lipid media and then TbACC protein
levels in total cell lysates were analyzed by SDS-PAGE and western blotting
using streptavidin-HRP (SA-HRP), which binds to the biotin prosthetic group of
ACC (Nikolau et al., 1985; Haneji and Koide, 1989). Other biotinylated proteins
can also be detected using SA-HRP, however the genome of T. brucei shows the
presence of only one other biotinylated protein, the 71 kD α subunit of 3methylcrotonyl-CoA carboxylase (Tb927.8.6970), an enzyme involved in amino
acid degradation. TbACC is 243 kD, making it distinguishable from the other
biotinylated enzyme in T. brucei. In BFs, TbACC protein levels showed no
significant difference in cells grown in low, normal, or high lipid media (Fig. 2.2.A
and C). However, in PFs growth in low lipid media resulted in a significant 1.6fold increase in TbACC protein levels as compared to high lipid media (Fig. 2.2.B
and C).
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Figure 2.2: Environmental lipids affects TbACC protein levels in PF but not BF. BF (A.) and
PF (B.) WT cells were grown in low, normal, and high lipid media to mid-logarithmic stage.
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Lysates were prepared in the presence of HALT phosphatase inhibitor cocktail. 10 µg of total
protein/lane was resolved by 10% SDS-PAGE and transferred to nitrocellulose. TbACC was
detected by SA-HRP blotting (top panel) and the same blots were probed for tubulin as a loading
control (bottom panel). Representative blots are shown in A and B. (C.) Densitometric
quantification of three independent experiments. ACC signal was normalized to the tubulin
loading control. Mean ± SEM is shown. ** P ≤ 0.01 for difference between PF cells grown in high
lipid and low lipid media (Student’s t-Test).

Effect of environmental lipids on TbACC activity
To examine the effect of environmental lipids on TbACC activity, lysates were
prepared from cells grown in low, normal, and high lipid media and then assayed
for ACC activity. TbACC enzyme activity was assayed by measuring the
incorporation of [14C]CO2 from radiolabeled [14C]NaHCO3 in the presence of
acetyl-CoA and ATP into the acid-resistant product [14C]malonyl-CoA, which was
quantified by scintillation counting. In BFs, growth in high or low lipid media did
not affect TbACC activity, as compared to growth in normal lipid media. In
contrast, in PFs growth in high lipid media resulted in ~60% decrease in TbACC
activity compared to growth in low lipid media (Fig. 2.3).
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Figure 2.3: Environmental lipids affect TbACC activity in PF but not BF. BF and PF WT cells
were grown in low, normal, and high lipid conditions to mid-logarithmic stage. Lysates were
prepared in the presence of HALT phosphatase inhibitor cocktail, and equal amount of total
14

protein was assayed for ACC activity by measuring incorporation of [ C]NaHCO3 into the acidresistant malonyl-CoA product in the presence of ATP and acetyl-CoA. Values were first
normalized to “no ATP” negative control before averaging. Average values were then expressed
relative to that of normal media. Mean ± SEM of 3 independent experiments is shown. ** P≤ 0.01
for difference between PF cells grown in high and low lipid conditions (Student’s t-Test).

Effect of exogenous C18:0 FA on TbACC activity
To confirm that the change in activity of TbACC in different environmental lipids
was due to the lipid component of the media, we determined if addition of a
single FA can affect TbACC activity. PFs were first grown in low lipid media to
mid-logarithmic stage. The culture was then divided into 3 sub-cultures that were
either maintained in low lipid media, or supplemented with serum to equal the
high lipid media, or supplemented with 35 µM of stearate (C18:0) FA. ACC
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enzyme activity was assayed as described above. PFs supplemented with serum
(high lipid) or 35 µM C18:0 FA showed a ~25% and ~40% decrease,
respectively, in TbACC activity when compared to cells maintained in low lipid
media (Fig. 2.4).

Figure 2.4: PF TbACC activity is reduced upon addition of exogenous C18:0 FA. PF WT
cells were grown in low lipid conditions, then maintained in low lipid (Low Lipid) or supplemented
with serum (High lipid) or 35 µM C18:0 FA (Low Lipid + 35 µM C18:0). Hypotonic lysates were
assayed for ACC activity as described in Fig. 2.2. Values were normalized to the “no ATP” control
before averaging, then averaged values expressed relative to the cells grown in low lipid
conditions. Mean± SEM of 3 independent experiments is shown. **P≤ 0.01 for difference from low
lipid conditions (Student’s t-Test).

In silico analysis of potential phosphorylation sites in TbACC
To determine if TbACC might be phosphorylated, the TbACC protein
sequence (Tb 927.8.7100) was analyzed for potential serine, threonine, and
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tyrosine phosphorylation sites using the NetPhos 2.0 prediction software (Bloom
et al., 1999). The NetPhos 2.0 output indicated the presence of 52 serine, 33
threonine, and 19 tyrosine potential phosphorylation sites with a confidence
threshold ≥0.50 (Tables 2.1, 2.2, and 2.3). With a threshold of ≥ 0.90, there were
19 phosphorylation sites, consisting of 13 serine, 3 threonine, and 3 tyrosine
sites (Fig. 2.5.A and B).
To determine what kinases might potentially phosphorylate TbACC,
KinasePhos 2.0 was used to assess the TbACC protein sequence for kinasespecific phosphorylation sites (Wong et al., 2007). The output predicted the
presence of a total of 29 kinase-specific phosphorylation sites with a confidence
threshold >0.70 (Table 2.4) and included 20 protein kinase C (PKC) sites, 8
protein kinase A (PKA) sites, and 1 protein kinase B (PKB) site. Five of the sites
predicted by the NetPhos 2.0 software were coincident with 3 predicted PKC
sites and 2 predicted PKA with threshold of ≥ 0.90. Interestingly, no
phosphorylation sites specific to AMPK were predicted.
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Table 2.1: Predicted phospho-serine sites
Position
48
147
175
199
396
430
441
469
553
578
600
643
644
648
705
735
766
797
827
921
958
1046
1084
1143
1160
1195

Context
KGIDSVRSW
FLGPSAKAM
TVPWSGDEI
KAYISTAEE
PYDTSPIDF
FRPTSGRVE
AFKNSKECW
GHIFSSAET
LRMLSKRDE
TEFLSNYES
MGLTSPTEI
EKEPSSLRI
KEPSSLRIS
SLRISIGGK
PLRASTVGA
PDDPSKVAR
ERLDSLARA
RRLKSAFSD
RVVGSDHAT
VNLRSTGDG
LEEGSMMDL
ATAGSAENQ
SRCPSVCTV
FTYRSAHDW
VAPLSARRL
PKKKSVSFL

Score
0.521
0.717
0.926
0.913
0.918
0.994
0.885
0.681
0.997
0.990
0.995
0.507
0.925
0.989
0.655
0.719
0.988
0.910
0.747
0.929
0.932
0.945
0.852
0.991
0.961
0.991

Position
1197
1245
1279
1313
1315
1355
1370
1397
1465
1511
1575
1600
1720
1811
1815
1858
1874
1902
1918
1965
1999
2001
2048
2119
2125
2128
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Context
KKSVSFLEH
IRSDSTIKY
QVGKSYKWR
VIVSSSSGA
VSSSSGASA
TSSDSVQEQ
VEPPSGCPA
SLLPSRGDE
RFPLSRIPP
INPPSYYDS
RIGLSAEVK
YLVQSDYDE
YSDNSQLGG
FDRDSWVES
SWVESLEGW
ADPTSSEAF
WFPDSARKT
WRGFSGGMR
KFGASIVDN
YCDGSARGG
PRLRSLSPD
LRSLSPDHR
PWKDSRRRF
ELNVSTHNI
HNIVSPTSA
VSPTSASAE

Score
0.994
0.976
0.993
0.816
0.909
0.992
0.899
0.993
0.922
0.996
0.585
0.908
0.685
0.995
0.734
0.974
0.613
0.610
0.890
0.873
0.786
0.987
0.954
0.809
0.887
0.976

Table 2.2: Predicted phospho-threonine sites
Position
9
60
70
418
422
429
473
548
688
730
744
869
870
873
922
1079
1097
1140
1151
1179
1190
1210
1246
1674
1694
1782
1825
1845
1857
1878
2036
2068
2179

Context
SPVTTMRPQ
HTGNTEAVE
TVMATPEDL
AVRVTAEDT
TAEDTDEGF
GFRPTSGRV
SSAETREEA
TAACTLRML
VEEGTIVAE
VAEITPDDP
PREATEPWP
QVRETTGDT
VRETTGDTR
TTGDTRKVF
NLRSTGDGT
NLQQTSRCP
CRQFTEEEV
PRTFTYRSA
WREDTLIRN
VMYPTPFKE
VFHATPKKK
RACVTPRDL
RSDSTIKYP
ISIVTGRSV
RVIQTGDAP
DRDVTYEPS
KTVVTGRAT
ETRPTRKCK
PADPTSSEA
SARKTADAL
RMEATGVVR
SLAATLVER
LERTTAK

Score
0.941
0.601
0.566
0.687
0.636
0.845
0.872
0.665
0.817
0.975
0.850
0.922
0.910
0.871
0.893
0.909
0.932
0.978
0.930
0.868
0.979
0.986
0.604
0.818
0.700
0.773
0.823
0.846
0.905
0.821
0.778
0.526
0.899
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Table 2.3: Predicted phospho-tyrosine sites
Position
54
99
197
274
393
447
540
562
585
1249
1350
1478
1512
1594
1632
1664
1716
1754
1783

Context
RSWLYVHTG
NRNNYANVD
YEKAYISTA
LADDYGDCI
GEQPYDTSP
ECWGYFSVG
QQDVYIALT
NHGRYVSFL
ESESYVNRS
STIKYPKHN
MNSLYTSSD
ATELYLDPA
NPPSYYDSE
EEAEYLYLV
GEVRYVIRG
MSKNYSNVP
GKEVYSDNS
RWLDYVPPV
RDVTYEPSG

Score
0.858
0.904
0.970
0.561
0.907
0.934
0.597
0.744
0.985
0.607
0.846
0.955
0.866
0.827
0.936
0.658
0.952
0.665
0.905
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Table 2.4: Predicted kinase-specific phosphorylation sites
Site
T-8
T-108
S-166
T-338
T-401
S-531
T-744
S-797
S-912
S-939
T-1079
S-1084
T-1140
T-1190
S-1195
T-1246
S-1268

Kinase
PKC
PKC
PKC
PKC
PKC
PKC
PKB
PKA
PKA
PKA
PKC
PKA
PKC
PKC
PKA
PKC
PKC

Score
0.71
0.71
0.71
0.89
0.78
0.72
0.76
0.77
0.77
0.74
0.73
0.71
0.88
0.80
0.72
0.90
0.89
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A.

B.

Figure 2.5: Phospho-prediction analysis. The TbACC predicted protein sequence was
analyzed for potential phosphorylation sites using NetPhos 2.0 prediction software. (A.) Graph
showing the frequency vs. predicted sites of phosphorylation. (B.) Cartoon showing high
confidence (≥0.90) phosphorylation sites and their location in the TbACC protein. N, N-terminal
domain; BCD, biotin carboxylase domain; BCCP, biotin carboxyl carrier protein domain; CT,
carboxyl transferase domain; and C, C-terminal domain.
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TbACC is a phosphoprotein whose phosphorylation is affected by
environmental lipids
To confirm that TbACC is a phosphoprotein, T. brucei PF cells carrying a
C-terminally myc-tagged ACC in one of the genomic loci (PF ACC-myc) were
grown in low, normal, and high lipid media for 48 h, then metabolically labeled
with [32P]orthophosphate as the sole source of phosphate. [32P]orthophosphate
labeling of TbACC-my immunoprecipitates confirmed that TbACC is
phosphorylated in PFs (Fig. 2.6). Furthermore, TbACC-myc showed a 4-fold
increase in phosphorylation in high lipid media compared to normal lipid media,
while TbACC-myc showed an 80% decrease in phosphorylation in low lipid
media compared to normal media (Fig 2.6.A and B).

63

A.

B.

Figure 2.6: Effect of environmental lipids on PF TbACC phosphorylation via
32

[ P]phosphate labeling. PF ACC-myc cells were grown in normal lipid media to mid-logarithmic
32

phase. Cells were harvested and incubated with 1-2 mCi [ P]orthophosphate in low, normal, and
high lipid phosphate-free media for 16 h. TbACC-myc immunoprecipitates were resolved by SDSPAGE, transferred on nitrocellulose, and blots assessed by autoradiography (A., top panel).
Identically-loaded blots were prepared in parallel and probed for total TbACC by SA-HRP blotting
(A., bottom panel) (B.) Densitometric analysis of the blots in A. TbACC-myc phosphorylation
values were normalized to total TbACC loaded.
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We further confirmed TbACC phosphorylation using a non-radioactive
phospho-staining method. PF ACC-myc cells were grown in low, normal, and
high lipid media, and TbACC-myc immunoprecipitates were resolved by SDSPAGE and stained for phosphoproteins using a non-specific phosphoprotein gel
stain, Pro Diamond Q. TbACC-myc purified from the low, normal, and high lipid
growth condition showed different levels of phosphorylation (Fig. 2.7A and B).
Low lipid media resulted in a 50% decrease in TbACC phosphorylation compared
to normal lipid media. In contrast, high lipid media induced the highest level of
TbACC phosphorylation with an increase of 2.5-fold over that in normal lipid
conditions. Similar experiments performed in BF ACC-myc cells indicated that
phosphorylation of TbACC was not detected in BFs (Fig. 2.8).
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A.

B.

Figure 2.7: Effect of environmental lipids on PF TbACC phosphorylation via
phosphoprotein gel staining. PF TbACC-myc immunoprecipitates from cells grown in low,
normal, and high lipid media were prepared as described for Fig. 2.6, resolved by SDS-PAGE,
and the gels stained with Pro Diamond Q phosphoprotein gel stain and imaged under UV (A.,
upper panel). Identically-loaded gels prepared in parallel were transferred to nitrocellulose and
the blots probed for total TbACC by SA-HRP blotting (A., lower panel). (B.) Densitometric
analysis of 3 independent experiments. PF TbACC-myc phosphorylation values (ACC-p) were
normalized to total TbACC-myc loaded (ACC-t). Mean± SEM is shown. *, P≤ 0.01 for differences
between high lipid and low lipid conditions (Student’s t-Test).
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Figure 2.8: Effect of environmental lipids on BF TbACC phosphorylation via
phosphoprotein gel staining. BF TbACC-myc immunoprecipitates from cells grown in low,
normal, and high lipid media were analyzed by Pro Diamond Q phosphoprotein gel staining as
8

described for Fig. 2.6, except 5 x 10 cells were used. Upper panel, UV imaging of
phosphoprotein gel staining of TbACC (ACC-p). Lower panel, SA-HRP blotting for total TbACC
(ACC-t) of identically-loaded blots processed in parallel.

Phosphorylation reduces the activity of TbACC-myc
To determine the effect of phosphorylation on TbACC activity, PF TbACCmyc cells were grown in high lipid media and TbACC-myc isolated by pull-down
with anti-myc sepharose beads. TbACC-myc-bound beads were treated with
lambda phosphatase or left untreated as a control. The TbACC activity of the
TbACC-myc bound to the beads was assayed as described previously. To
confirm successful dephosphorylation, TbACC-myc pull-downs were also
assessed by SDS-PAGE and Pro Diamond Q phosphoprotein gel staining as
described previously. Phosphoprotein staining confirmed successful
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dephosphorylation of TbACC-myc by lambda phosphatase treatment (Fig. 2.9A).
Dephosphorylation of TbACC-myc resulted in a 2-fold increase in TbACC-myc
activity as compared to the untreated control, indicating that phosphorylation is
an inhibitory modification (Fig. 2.9B).

A.

B.

Figure 2.9: Phosphorylation of TbACC reduces activity. PF TbACC-myc cells were grown in
normal media to mid-log phase. TbACC-myc was pulled down by anti-myc sepharose beads and
directly treated with 400 U of lambda phosphatase or mock treated as a control. TbACC-myc pulldowns were assessed for phosphorylation by SDS-PAGE and phosphoprotein staining. (A.)
Representative UV image of phosphoprotein gel staining (upper panel) and SA-HRP blotting of
TbACC-myc pull-downs processed in parallel (lower panel). (B.) Phosphatase and mock-treated
TbACC-myc pull-downs were assayed for ACC activity. Values were normalized to “no ATP”
control. Mean ± SEM of 3 independent experiments are shown. *, P≤0.01 for difference between
phosphatase-treated and untreated (Student’s t-Test).
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DISCUSSION
It is well documented that T. brucei can readily take up and use lipids,
including FAs, from its environment (Dixon et al., 1971; Voorheis, 1980; Bowes et
al., 1993; Coppens et al., 1995; Lee et al., 1999). Given that T. brucei can satisfy
its FA requirements either through uptake from the host or through de novo
synthesis, the parasite may have a mechanism to modulate FA synthesis in
response to environmental lipid availability. We hypothesized that TbACC serves
as a regulatory control point and thus, is regulated by environmental lipids. As
serum is the sole source of lipid in the media, we determined the effect of
modulating the serum lipids in the growth media on TbACC expression and
activity.
Quantitative RT-PCR analysis of TbACC mRNA levels showed no
significant difference when BF and PF T. brucei were grown in low, normal, or
high lipid media. Thus, TbACC does not appear to be transcriptionally regulated.
This result is consistent with studies that indicate minimal transcriptional
regulation in T. brucei, due to their polycistronic mode of transcription and the
absence of classical RNA Pol II promoters (Campbell et al., 2003; Palenchar and
Bellofatto, 2006; Günzl et al., 2007; Martinez-Calvillo et al., 2010).
We next looked at TbACC protein levels in cells grown in low, normal, and
high lipid media by western blot analysis. In BFs, there was no significant
difference in TbACC protein levels. However, in PFs we observed the highest
levels of TbACC protein in the low lipid media and the lowest level in the high
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lipid media. Growth in low, normal, or high lipid media had no effect on TbACC
enzyme activity in BFs, but in PFs, TbACC was highest in the low lipid media and
lowest in the high lipid media. The reduction of TbACC activity seen when low
lipid media was supplemented with C18:0 FA confirms the idea that the
regulation of PF TbACC is due to the lipid component of the media. Together,
these results demonstrate that TbACC is regulated post-transcriptionally in PFs
in response to environmental lipids, both at the level of protein and activity.
TbACC protein levels may be regulated due to protein degradation in high lipid
conditions. Control at the level of protein stability occurs due to translational and
post translational regulation in Trypanosomes (Torri et al., 1993; Gale et al.,
1994). Proteasomal mediated degradation has already been established in
T.brucei (Li et al., 2002). This selective degradation can be due to environmental
sensing and post translational modification of TbACC resulting in targeted
TbACC degradation in high lipid environment.
In other organisms, it is well documented that ACC activity is regulated
through phosphorylation by AMPK and PKA (Hardie et al.,1992; Brownsey et al.,
2006). Metabolic labeling experiments demonstrated the presence of at least four
hormonal-responsive phosphorylation sites in mammalian ACCs (Brownsey et
al., 1992; Hardie et al., 1992). Glucagon treatment or high cellular AMP levels
lead to the rapid phosphorylation and inactivation of ACC. Because ACC is
regulated by phosphorylation in all organisms studied to date (Kim, 1983; Kim et
al., 1989), we hypothesized that TbACC is also regulated by phosphorylation.
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First, in silico analysis of the TbACC protein sequence for potential
phosphorylation sites and kinase-specific sites revealed multiple predicted highconfidence sites, including consensus sites for PKA, PKC, and PKB kinases,
homologs for which are present in the T. brucei genome (Nett et al., 2009).
However, none of these predicted phosphorylation sites corresponded with
known, highly conserved, phosphorylation sites in human and yeast ACCs
(Kimberly Paul, personal communication). Interestingly, no sites for the bestcharacterized ACC kinase, AMPK, were predicted despite the fact that AMPK is
present in T. brucei (Clemmens et al., 2009). Although a negative observation
and thus inconclusive, the sole phosphoproteomic study in T. brucei available at
the time we initiated these studies showed no evidence that TbACC was
phosphorylated (Nett et al., 2009).
Metabolic labeling with [32P]orthophosphate and phosphoprotein staining
of PFs confirmed that TbACC is phosphorylated in PF T. brucei, consistent with
the detection of ACC phosphorylation in other species by 32P-labeling (Witters,
1981; Thampi and Wakil, 1985). Further, these studies revealed that TbACC is
differentially phosphorylated in PFs in response to environmental lipids. The
relative phosphorylation level of TbACC increased in the presence of high
environmental lipid levels and decreased as the environmental lipid levels
decreased. This is consistent with the FA induction of the AMPK signaling
cascade in response to environmental lipids observed in muscle (Li et al., 2013).
We also demonstrated that dephosphorylation of TbACC leads to an increase in
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its activity, indicating that phosphorylation is an inactivating post-translational
modification of TbACC. These observations on TbACC phosphorylation are
consistent with work on ACC regulation in humans and yeast, which
demonstrated that treatment of cells with starvation-stimulated hormones such as
glucagon leads to rapid phosphorylation and inactivation of ACC (Hardie et al.,
1992). Likewise, dephosphorylation of chicken liver ACC by treating it with
protein phosphatase caused a 5-fold increase in ACC activity (Wada and
Tanabe, 1983).
We propose that when PFs have an adequate supply of lipid in their
environment, they rely on uptake of exogenous fatty acids from the media and
correspondingly phosphorylate and downregulate TbACC. However, under
limiting lipid conditions, the parasite dephosphorylates TbACC, thereby activating
it in order to synthesize its own FAs. This idea is consistent with the general
upregulation of FA synthesis seen when PFs were grown in low lipid media (Lee
et al., 2006) and studies showing that RNAi of TbACC or another FA synthesis
enzyme enoyl-CoA reductase had no effect on growth in normal or high lipid
media, but reduced growth only in low lipid media (Lee et al., 2006; Vigueira et
al., 2011).
The phosphorylation of human ACC isoforms is complex, involving several
phosphorylation sites, thus the impact of a specific phosphorylation state and
catalytic activity has been controversial (Lane et al., 1974; Kim, 1979; Tipper and
Witters, 1982; Tipper et al., 1983). Given the number of potential phosphorylation
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sites in TbACC, phosphoregulation of TbACC may also be subject to complex
regulation by multiple kinases. Supporting this idea, a recent phosphoproteomic
study in T. brucei (Urbaniak et al., 2013) identified three TbACC
phosphopeptides, corresponding to Ser5, Ser1999, and Ser2001. The latter two
phosphoserine sites were predicted by NetPhos 2.0 as potential phosphorylation
sites with confidence scores of 0.786 and 0.987, respectively. None of the three
phosphoserine sites were predicted by NetPhosK 1.0 to be a kinase-specific site,
possibly owing to the divergence of consensus sites between T. brucei kinases
and other eukaryotic kinases (Brownsey et al., 1992; Hardie et al., 1992). Future
work will be needed to determine the identity of the TbACC kinase(s) and the role
of each phosphorylation site.
In contrast to PFs, we observed no changes in TbACC protein levels or
activity in BFs grown in different lipid conditions. In addition, we observed no
phospholabeling of TbACC in BFs grown in low, normal, or high lipid media.
These data suggest that BF TbACC does not appear to be regulated by
environmental lipids and that under typical culture conditions, BF TbACC is
constitutively dephosphorylated and active. We have demonstrated, however,
that phosphorylated TbACC can be detected in BFs, when the cells were treated
with a compound, epigallocatechin gallate, which is a known activator of AMPK
(Vigueira et al., 2012).
Constitutive activation of TbACC in BFs can have several possible
explanations. First, there may be a difference in the sensitivity of BFs to
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environmental lipids compared to PFs. Perhaps the altered lipid levels in the low
or high lipid media did not achieve the threshold needed for BFs to modulate
their TbACC expression or activity. We attempted to further lower the lipid in
media by delipidation or reduction of serum, but the resulting media did not
support T. brucei growth.
Second, there may be a high demand of FAs in BFs due to the VSG coat,
which plays a vital role in immune evasion in T. brucei (Donelson, 2003). The
VSG GPI-anchors contain exclusively myristate, a relatively scarce FA in blood
(Paul et al., 2001), and at any given time, a single parasite expresses around a
10 million copies of VSG, each of them anchored by two myristates (Ferguson
and Cross, 1984). Thus, BF T. brucei may rely on TbACC and ongoing FA
synthesis to make enough myristates to maintain the VSG coat.
Third, constitutive activation of TbACC and ongoing FA synthesis may be
required to support a second immune evasion tactic in BF T. brucei, the
upregulation of endocytosis (Field and Carrington, 2009). The rate of endocytosis
in BFs is 10-fold higher than that of PFs (Natesan, et al., 2007), and this high rate
of endocytosis is thought to enable BF T. brucei to clear surface-bound
antibodies and evade complement-mediated lysis (Balber et al., 1979; Ferrante
and Allison, 1983; Donelson et al., 1998). Clearance of antibody from the surface
is achieved by internalization of VSGs bound to antibodies into a recycling
endocytic pathway, where after sorting, the antibody is degraded and VSG is
recycled back to the surface (Donelson et al., 1999; Field and Carrington, 2009).
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The high rate of membrane turnover needed to sustain this rapid rate of
endocytosis and recycling may require a high rate of TbACC activity and FA
synthesis in BFs in order to maintain membrane homeostasis. Studies from our
lab provide support for the idea that activation of TbACC is required to sustain
high rates of endocytosis (Mcknight, 2012). RNAi of ACC in BF T. brucei resulted
in a reduction in both fluid phase and receptor-mediated endocytosis, slowed
kinetics of antibody clearance, and increased susceptibility to killing by
complement-mediated lysis (McKnight, 2012).
In summary, the work presented in this chapter demonstrate that TbACC
is regulated by environmental lipids in PFs but not in BFs. We showed that T.
brucei regulates its FA metabolism so that FA synthesis is down-regulated in
lipid-rich environments and is upregulated when environmental lipids are limiting.
These results also suggest that T. brucei can transduce its environmental lipid
status into regulatory signals that not only alter TbACC protein levels but also its
activity, suggesting multiple post-transcriptional regulatory mechanisms. Finally,
we have demonstrated that one such environmental regulatory mechanism is
phosphorylation, which occurs under high lipid conditions and serves to reduce
TbACC activity.
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MATERIALS AND METHODS
Reagents
All chemicals and reagents used in this study were purchased from
Thermo Fisher Scientific and Sigma except: Iscove’s Modified Dulbecco’s
Medium (IMDM) and Minimum Essential Media (MEM) (Invitrogen), Serum Plus
(JRH Biosciences), and delipidated Fetal Bovine Serum (Cocalico Biologicals).

T. brucei strains and growth media
Wild-type PF and BF T. brucei strain 427 were a kind gift from Dr. Paul
Englund (Johns Hopkins School of Medicine). ACC-myc PF cell line expressing
one genomic loci of ACC with a C-terminal myc epitope tag was developed by
Dr. Patrick Vigueira (Vigueira et al., 2011). A BF ACC-myc cell line was
generated using the same method as in (Vigueira et al., 2011). Correct
integration of myc epitope tag was verified using diagnostic PCR and western
blotting.
Serum is the only source of lipids in the T. brucei growth media. Three
different sera were used to prepare media: Fetal Bovine Serum (FBS),
delipidated Fetal Bovine Serum (dFBS), and Serum Plus (SP) (see Table 2.5 for
media formulations). According to the manufacturers, both dFBS and SP have
20% of the lipids found in FBS. The normal growth medium for PFs is SDM-79
(Brun and Shonenberger, 1979) supplemented with heat-inactivated 10% FBS,
making the medium 10% total serum lipids. For BFs, the normal growth medium
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is HMI-9 (Hirumi and Hirumi, 1989) supplemented with heat-inactivated 10% FBS
and 10% SP, making the medium 12% total serum lipids.
To prepare low lipid media for PFs, heat-inactivated 10% dFBS replaced
the FBS giving a final concentration of 2% total serum lipids. BF low lipid media
was prepared with 10% heat-inactivated dFBS and 10% SP, giving a final
concentration of 4% total serum lipids. For both BFs and PFs, high lipid media
was prepared by doubling the heat- inactivated FBS, resulting in a final of 20%
and 22% total serum lipids for BF and PF media, respectively.

TABLE 2.5: Formula for low, normal, and high lipid T. brucei growth media

BSF

PCF

Condition Delipidated Fetal
Serum
Bovine
Serum
Low
10%
0%

Serum
Plus

Serum lipid
Equivalents

10%

4% (~0.2X)

Normal

____

10%

10%

12% (1X)

High

____

20%

10%

22% ~(2X)

Low

10%

0%

____

2% (0.2X)

Normal

____

10%

____

10% (1X)

High

____

20%

____

20% (2X)

Lysate preparation
Hypotonic lysates were prepared from 5 x 108 cells as described (Morita et
al., 2000) or from 1 x 109 cells as described (Bangs 1993; Roggy and Bangs,
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1999). For both lysis methods, a protease inhibitor cocktail (1 µg/ml Leupeptin,
0.1 mM tosyllysine chloromethyl ketone hydrochloride (TLCK)) and HALT
phosphatase inhibitor cocktail (Thermo Scientific) were added during the lysis
Hypotonic lysates were sheared by passage through a 271/2 gauge needle three
times, and lysates were clarified by centrifugation at 4 ºC at 1,000 x g (10 min.)
followed by 16,000 x g (10 min.). RIPA (radioimmunoprecipitate assay) lysates
were prepared from 1 x 109 cells/ml as described (Vigueira et al., 2011). Cell
lysates were centrifuged for 30 min. at 16,000 x g at 4 ºC to remove cellular
debris.

Quantitative reverse transcriptase PCR
BF and PF WT cells (3-5 x 106) were grown to mid-logarithmic stage and
washed in bicine-buffered saline glucose buffer (Raper et al., 1993). Total RNA
was extracted using Aurum Total RNA Mini Kit (Bio-Rad) according to the
manufacturer’s protocol, except RNA was eluted using 40 µl of elution buffer.
T. brucei ACC-specific primers were designed using Primer3 (Rozen and
Skaletsky, 2000): Forward ACC primer, 5’-TTT CGT AAG TTG AAG TCT GG-3’;
and reverse ACC primer, 5’-CTT AGT CGG ATC AAT GTC AC-3’. Actin was
used as a control and actin-specific primers were a kind gift from Dr. Meredith
Morris (Clemson University): forward Actin primer, 5’-GCC ACG TAT TTC CAT
CCA TC-3’; and reverse Actin primer, 5’-CCT GAG CTT CAT CAC CAA CA-3’.
cDNA synthesis was performed on 100-200 ng total RNA using the iScript cDNA
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Synthesis Kit (Bio-rad) using the manufacturer’s protocol. The resultant cDNA
was used as template with 0.2 μM of each primer pair and the SensiFAST SYBR
& Fluorescein Mix (Bioline) in quantitative PCR with 1 cycle at 95 °C for 2 min,
and then 40 cycles as follows: 95 °C for 30 s., 57 °C for 1 min., and 72 °C for 30
s. β-actin served as the endogenous control. ΔΔCt method was used to calculate
the relative expression levels.

Western blotting
Proteins were resolved by 10% SDS-PAGE and transferred to
nitrocellulose membrane. For streptavidin blotting, the membrane was blocked in
2.5% nonfat dry milk, 1X Tris Buffered Saline (TBS), 0.05% Tween 20 for ≥ 1 h.
and washed three times (5 min. each) in streptavidin wash buffer (0.2% nonfat
dry milk, 1X TBS, 0.05% Tween 20). To probe for ACC, blots were probed with
1:200 SA-HRP (Pierce), which recognizes the biotin prosthetic group (Nikolau et
al., 1985) for ≥ 2 h. The blots were then washed twice with streptavidin wash
buffer and twice with 1X TBS, 0.05% Tween 20 before development with Super
Signal West Pico Chemiluminescent substrate kit (Thermo Scientific).
For anti-tubulin blotting, membranes were blocked in 2.5% nonfat dry milk,
1X TBS, 0.05% Tween 20 for ≥ 1 hour then probed with mouse anti-tubulin
(Pierce) diluted 1:50,000 in blocking buffer. The blots were washed thrice in
blocking buffer and then probed with peroxidase-conjugated goat anti-mouse IgG
(Rockland) diluted 1:10,000 in blocking buffer. Blots were then washed twice with
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blocking buffer and twice with 1XTBS, 0.05% Tween 20 before chemiluminescent
development.
For anti-c-myc blotting, membranes were blocked in 5% nonfat dry milk,
1X TBS, 0.05% Tween 20 for ≥ 1 h., then probed for myc-tagged ACC using
mouse anti-c-myc monoclonal antibodies (sc 40, Santa Cruz Biotechnology)
diluted 1:250 in blocking buffer. The blots were washed twice in blocking buffer
and then probed with peroxidase-conjugated goat anti-mouse IgG (Rockland)
diluted at 1:10,000 in blocking buffer. Blots were then washed twice with blocking
buffer and twice with 1X TBS, 0.05% Tween 20 before chemiluminescent
development. Appropriately exposed blots were analyzed by densitometry using
Image J software (NIH) and values normalized to the indicated loading control.

ACC activity assay
PF and BF cells were grown to logarithmic stage (1-2.5 x 107 PF cells/ml
and 2.5-5 x 106 BF cells/ml) in low, normal and high lipid media. Hypotonic
lysates were prepared in the presence of 1X HALT phosphatase inhibitor cocktail
(Thermo Scientific). To remove endogenous CoA substrates and ATP, lysates
were fractionated through a 1.5-2 ml G-50 sephadex column equilibrated in biotin
carboxylase buffer (50 mM Tris-Cl pH 8.0, 5 mM MgCl2, 5 mM DTT)
supplemented with 1X HALT phosphatase inhibitor cocktail. The protein
concentration of the chromatographed lysates were determined using the
Bradford protein assay kit (Bio-Rad) using BSA as a standard. Equal protein was
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assayed for ACC activity as described (Vigueira et al., 2011). ACC activity was
normalized to the background (no ATP) and expressed as a percent of ACC
activity in normal lipid media. Statistical significance of differences was assessed
using Student’s T-test (Microsoft Excel).

TbACC-myc immunoprecipitation
TbACC-myc was purified from hypotonic PF and BF lysates using Pierce
c-myc-Tag IP/Co-IP kit (Thermo-Fischer). The manufacturer’s protocol was
modified as follows to obtain the maximum yield: hypotonic lysates (500 µl or 5 x
108 cell equivalents) were incubated with 10-15 µl of anti-myc agarose beads
overnight at 4 °C with constant end-over-end mixing. Then the lysate/beads
mixture was loaded into an empty spin column and unbound proteins removed
with 3 washes with 1X TBS, 0.5% Tween 20. Bound TbACC-myc was eluted
using 150 mM glycine pH 2.8, added 10 µl at a time. Elution volumes were 100 µl
and 60 µl for PF and BF TbACC-myc, respectively. Eluted TbACC-myc was
immediately neutralized by the addition of 20 µl (PF) and 10 µl buffer (BF) of 100
mM Tris-Cl pH 9.5).

Metabolic [32P]labeling of TbACC-myc
PF ACC-myc cells were grown in normal medium to mid-logarithmic phase
(1-2.5 x 107 cells/ml). The cells were harvested by centrifugation and washed 3X
in Cunningham’s phosphate-free medium (Kaminsky et al., 1983). Cells were
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resuspended to a final concentration 0.5 x 108 cells/ml in Cunningham’s
phosphate-free medium supplemented with dialyzed serum to generate low,
normal, and high lipid media (Table 2.1). Cells were then incubated with 1-2 mCi
[32P]orthophosphate (ARC # 0103, 350 mCi/ml) for 16 h. at 28 ºC/ 5% CO2 . As a
control, cells were incubated with the equivalent concentration of non-radioactive
phosphate (10 mM KPi, pH 7.0). After labeling, the cells were harvested,
hypotonic lysates prepared in the presence of HALT phosphatase inhibitor
cocktail, and TbACC-myc purified by immunoprecipitation. TbACC-myc
immunoprecipitates were resolved using SDS-PAGE and transferred to
nitrocellulose. TbACC-myc blots were first assessed by autoradiography by
exposing it to X-ray film for 10 days at room temperature. The same blot was
then blotted using SA-HRP for total ACC as a loading control. Autoradiographs
and blots were quantified by densitometry using ImageJ software (NIH) and
values normalized using the loading control.

Phosphoprotein gel staining
Tb ACC-myc immunoprecipitates from hypotonic lysates of PF TbACCmyc cells grown in low, normal, and high lipid media were resolved by SDSPAGE, and the gels were processed and stained with Pro Diamond Q
Phosphoprotein Gel stain (Invitrogen) according to the manufacturer’s directions.
Phosphostained gels were imaged under UV using the Gel Doc XR Imaging
System (Bio-Rad). In parallel, an identically-loaded non-stained gel was
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transferred to nitrocellulose and probed with SA-HRP to detect total ACC loaded.
Appropriately exposed blots and gel images were analyzed by densitometry
using Image J software (NIH). Values for phosphorylated ACC-myc were
normalized to total ACC loaded.

Lambda phosphatase treatment
Hypotonic lysates prepared from PF TbACC-myc cells grown to log-phase
in normal lipid media were incubated with the Pierce ProFound c-Myc Tag IP/CoIP kit (Thermo Fischer) for 16h at 4 ºC with constant end-to-end mixing. TbACCmyc bound beads were washed 5X with 500 µl BC buffer then treated with 400 U
of Lambda phosphatase (NEB) in a final volume of 200 µl in the provided buffer
according to the manufacturer’s protocol. As a control, TbACC-myc bound beads
were incubated as above, but Lambda phosphatase was omitted. Treated or
control TbACC-myc bound beads were then washed 2X in BC buffer and
assayed for ACC activity as described above by adding assay components
directly to TbACC bound beads.
Phosphatase treated and control TbACC-myc immunoprecipitates were
resolved by SDS-PAGE and the gels stained with Pro Diamond Q phosphostain.
In parallel, an identically-loaded non-stained gel was transferred to nitrocellulose
and probed with SA-HRP to detect total ACC loaded. Appropriately exposed
blots and gel images were analyzed by densitometry using Image J software
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(NIH). Values for phosphorylated TbACC-myc were normalized to total ACC
loaded.
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CHAPTER 3
EFFECTS OF THE GREEN TEA CATECHIN (-)-EPIGALLOCATECHIN
GALLATE ON Trypanosoma brucei
Patrick A. Vigueira, Sunayan S. Ray, Ben A. Martin, Marianne M. Ligon, Kimberly
S. Paul *

ABSTRACT
The current pharmacopeia to treat the lethal human and animal diseases caused
by the protozoan parasite Trypanosoma brucei remains limited. The parasite’s
ability to undergo antigenic variation represents a considerable barrier to vaccine
development, making the identification of new drug targets extremely important.
Recent studies have demonstrated that fatty acid synthesis is important for
growth and virulence of T. brucei brucei, suggesting this pathway may have
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therapeutic potential. The first committed step of fatty acid synthesis is catalyzed
by acetyl-CoA carboxylase (ACC), which is a known target of
(-)-epigallocatechin-3-gallate (EGCG), an active polyphenol compound found in
green tea. EGCG exerts its effects on ACC through activation of AMP-dependent
protein kinase, which phosphorylates and inhibits ACC. We found that EGCG
inhibited TbACC activity with an EC50 of 37 µM and 55 µM for bloodstream form
and procyclic form lysates, respectively. Treatment with 100 µM EGCG induced a
4.7- and 1.7- fold increase in TbACC phosphorylation in bloodstream form and
procyclic lysates. EGCG also inhibited the growth of bloodstream and procyclic
parasites in culture, with a 48 h EC50 of 33 µM and 27 µM, respectively, which is
greater than the EGCG plasma levels typically achievable in humans through
oral dosing. Daily intraperitoneal administration of EGCG did not reduce the
virulence of an acute mouse model of T. b. brucei infection. These data suggest
a reduced potential for EGCG to treat T. brucei infections, but suggest that
EGCG may prove to be useful as a tool to probe ACC regulation.

INTRODUCTION
The protozoan parasite Trypanosoma brucei (sub-species gambiense and
rhodesiense) are the causative agent of African sleeping sickness, a fatal human
disease that ranges across sub-Saharan Africa. In addition to causing substantial
morbidity and mortality in humans, a third sub-species, T. brucei brucei is
responsible for causing nagana, a livestock disease that results in wasting and
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death. Nagana imposes a tremendous economic burden on the region, causing
4.5 billion dollars in economic losses each year (FAO, 2007). Vaccine
development is confounded by the parasite’s ability to switch its surface coat
through antigenic variation (Horn and McCulloch, 2010). Chemotherapeutics are
relied upon to battle the disease, yet currently approved drugs cause undesirable
side effects, are subject to failure, and can be too expensive for citizens of
economically depressed regions (Castillo et al., 2010). To meet this urgent need,
investigation of existing compounds are an important avenue to identify potential
new drugs that are effective, safe, and economical.
Green tea is amongst the most widely consumed beverages worldwide
and is often touted for its wealth of medicinal effects (Moon et al., 2007; Khan
and Mukhtar, 2008; Thielecke and Boschmann, 2009; Ahmed, 2010). The beststudied active components of green tea are the catechins, of which (−)epigallocatechin-3-gallate (EGCG) is one of the most abundant (Lin et al., 2003).
In addition to numerous other pathways, EGCG has been demonstrated to inhibit
fatty acid synthesis (Wang and Tian, 2001; Brusselmans et al., 2003) through its
effect on the regulation of acetyl-CoA carboxylase (ACC) (Huang et al., 2009).
ACC catalyzes the first committed step in fatty acid synthesis: the ATPdependent carboxylation of acetyl-CoA, which provides the two-carbon donor,
malonyl-CoA, for fatty acid synthesis (Tong and Harwood, 2006). ACC is
negatively regulated by phosphorylation by AMP-activated protein kinase
(AMPK), a key regulator of cellular energy metabolism (Barber et al., 2005;
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Brownsey et al., 2006). EGCG treatment activates AMPK, leading to increased
phosphorylation of human ACC, which resulted in its inhibition (Moon et al.,
2007; Huang et al., 2009).
In T. b. brucei, both the cytoplasmic and mitochondrial fatty acid synthesis
pathways are important for growth in culture and virulence in mouse models (Lee
et al., 2006; Lee et al., 2007; Stephens et al., 2007; Vigueira and Paul, 2011).
We have recently demonstrated that RNA interference (RNAi)-mediated gene
knock-down of ACC in T. b. brucei reduced fatty acid elongation activity in intact
cells and reduced virulence in a mouse model of infection (Vigueira and Paul,
2011). In addition, treatment with thiolactomycin, an inhibitor of fatty acid
synthetase, inhibited fatty acid synthesis activity and growth of T. b. brucei in
culture (Morita et al., 2000). Taken together, these results suggest that fatty acid
synthesis has the potential to be an effective drug target in T. brucei. Here, we
examined the effect of EGCG on T. b. brucei and found that physiologically
relevant levels of EGCG had no effect on growth in culture and did not reduce
virulence in a mouse model of infection, while higher levels of EGCG decreased
TbACC activity, likely through an increase in TbACC phosphorylation. These
data suggest that although EGCG inhibits T. b. brucei ACC activity, EGCG is a
questionable candidate for further development as a potential cure for T. brucei
infection. However, EGCG may be a useful pharmacological tool to investigate
the signaling pathways governing phospho-regulation of TbACC.
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RESULTS
To investigate whether EGCG could be used to target ACC in T. b. brucei,
we first tested EGCG for its ability to inhibit TbACC enzymatic activity in whole
cell lysates from two different life cycle stages: the procyclic form (PF) found in
the fly midgut, and the mammalian bloodstream form (BF). Because of the known
mode of action of EGCG on mammalian ACC phosphorylation, we sought to
preserve any potential changes in phosphorylation caused by EGCG by adding
HALT, a broad-spectrum phosphatase inhibitor, to the cell lysate. In the presence
of HALT, EGCG reduced ACC activity in both BF and PF lysates, with an EC50 of
29 ± 1.3 µM (n=3) and 55 ± 2.4 µM (n=3), respectively (Fig. 1A and B). HALT
treatment alone had no effect on ACC activity (data not shown). However, in the
absence of HALT, we observed no inhibition of TbACC activity in lysates by
EGCG. Thus, EGCG treatment inhibited ACC activity only in the presence of
phosphatase inhibitors. Although the effect of EGCG on ACC activity in lysates
has not been previously measured, our observations are consistent with the
reported mode of action of EGCG on ACC by increasing ACC phosphorylation
(Collins et al., 2007; Huang et al., 2007; Moon et al., 2007, Huang et al., 2009;
Murase et al., 2009). That no effect was observed in the absence of HALT rules
out a more general inhibitory “tannin” effect on the ACC enzyme (Wink 2008).
Thus, we propose that HALT, by inhibiting the endogenous phosphatases in the
lysate, preserved an EGCG-driven increase in ACC phosphorylation, resulting in
decreased TbACC activity.
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To more directly examine the effect of EGCG treatment on TbACC
phosphorylation, we used BF and PF cell lines in which the C-terminus of one
TbACC allele was fused to the c-myc epitope (TbACC-myc), which allows for
expression of TbACC-myc at endogenous levels under the native promoter
(Vigueira and Paul, 2011; and this study). BF and PF TbACC-myc lysates were
treated with 100 µM EGCG or DMSO as solvent control in the presence of HALT.
After EGCG treatment, TbACC-myc immunoprecipitates were resolved by SDSPAGE and phosphorylated TbACC detected by in-gel phospho-staining with Pro
Q Diamond stain (Fig. 2A and B, upper panels, respectively). As a loading
control, identically-loaded gels were transferred to nitrocellulose and total ACC
detected by blotting with streptavidin-HRP (Fig. 2A and B, lower panels).
Densitometry of the phospho-stained gels revealed that EGCG treatment
resulted in a statistically significant 4.7 ± 0.12 -fold (P<0.0001; n=3) and
1.7 ± 0.20 -fold (P<0.05; n=3) increase in phosphorylation of TbACC in BFs and
PFs, respectively. This increase in phosphorylation is correlated with the
observed inhibition of TbACC activity in BF and PF lysates (Fig. 1A and 1B). It is
possible that ACC-myc is inefficiently or aberrantly phosphorylated compared to
native ACC, which might mask the true response of ACC to EGCG treatment.
However, the facts that immunoprecipitated ACC-myc was also highly active and
ACC-myc exhibited the same subcellular fractionation as native ACC (Vigueira
and Paul, 2011) argue against this idea. In addition, similar increases in ACC
phosphorylation were observed in mammalian cells after treatment with similar

100

concentrations of EGCG (50-400 µM) (Huang et al., 2007; Moon et al., 2007;
Huang et al., 2009; Murase et al., 2009). Taken together, the results shown in
Fig. 1 and 2 indicate that ACC is phosphorylated in both BFs and PFs of
T. brucei, and that EGCG treatment leads to increased TbACC phosphorylation
and correspondingly decreased TbACC activity. It is unknown how EGCG
treatment leads to phosphorylation and inactivation of TbACC. In mammalian
cells, how EGCG activates AMPK is not well understood, but occurs via
activation of one or more upstream kinases (e.g. liver kinase B1 (LKB1) and
calmodulin-dependent protein kinase (Cask) in a process that may involve the
production of reactive oxygen species (ROS) via oxidation of EGCG (Sang et al.,
2005; Hou et al., 2005; Hwang et al., 2007; Collins et al., 2007; Moon et al.,
2007; Murase et al., 2009; Hou). Future work will be needed to determine the
identity of the upstream TbACC kinase(s) and the role of ROS in their signaling.
We next examined the effect of EGCG on T. b. brucei growth in culture.
Orally administered EGCG is rapidly cleared from the body (Ullmann et al., 2003;
Chow et al., 2005). In humans, repeated daily oral administration of EGCG can
achieve a maximum plasma concentration of ~1 µM for 5-6 h (Ullmann et al.,
2004). A 6 day treatment of BF cells at these physiological EGCG concentrations
(0.1–1 µM) caused no change in growth or doubling time (Fig. 3A and B). Next,
we tested higher EGCG concentrations (5–50 µM), and observed a statistically
significant reduction in cell growth over 48 h (Fig. 3C and D), with an EC50 of
34 ± 2.4 µM and 25 ± 2.7 µM for BF and PF parasites, respectively (P<0.01,
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n=4). These values are consistent with the trypanocidal activity of EGCG (IC50
20.2 µM at 72 h) previously reported for T. b. rhodesiense (Tasdemir et al.,
2006). Our previous data showed that TbACC is largely unnecessary in BF
parasites cultured in vitro and is only required when PF parasites are cultured in
low-lipid media (Vigueira and Paul, 2011). Thus, we contend that inhibition of
TbACC by EGCG should have little consequence on T. b. brucei growth in
culture. Consequently, we attribute the reduction in growth observed with EGCG
concentrations >5 µM to other previously described target(s) of EGCG (Ahmed,
2010; Singh et al., 2011), rather than to its inhibition of TbACC.
Finally, we examined the effect of EGCG treatment on the course of T. b.
brucei infection in mice. Although the EC50 values for EGCG for growth in culture
are greater than the achievable physiological concentrations in humans, there
were three reasons to justify testing EGCG in a mouse model of infection. First,
T. b. brucei exhibited condition-specific essentiality in the case of both TbACC
and enoyl-CoA reductase (EnCAR). PF ACC and EnCAR RNAi cell lines
exhibited slowed growth only when exogenous lipids were limited, and a TbACC
RNAi line had attenuated virulence in mice (Lee et al., 2006; Vigueira and Paul,
2011). Second, studies in rats showed that intravenous administration of EGCG
resulted in greater plasma half-life and in higher maximal plasma concentrations
than seen with the oral route of administration (Isbrucker et al., 2006; Misaka et
al., 2012). Third, previous studies of EGCG in mice have yielded promising
results for treatment of trypanosomiasis. T. cruzi mortality in mice and growth in
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culture was reduced with EGCG treatment (Paveto et al., 2004; Güida et al.,
2007). In addition, inflammation caused by T. b. brucei infection was reduced and
survivorship was extended with oral green tea supplementation (Karori et al.,
2008). Taken together, these observations suggest that first, parenteral
administration of EGCG might achieve therapeutic plasma concentration of
EGCG, and second, the requirement for ACC and thus the parasite’s sensitivity
to EGCG could be higher in vivo.
To test the ability of EGCG to clear a T. b. brucei infection in mice, we
administered daily IP injections of 4.13 mg/kg EGCG in sterile H2O two days prior
to infection and over the course of the trial. This EGCG concentration had been
previously determined not to cause mouse liver damage, though the actual
EGCG serum concentration was not determined (Güida et al., 2007). After 2
days of EGCG pre-treatment, Swiss mice were then infected with 1x105 BF wildtype 427 parasites as previously described (Bacchi et al., 2009), and time until
death (or humane end-point) was determined. In this infection model, EGCG
treatment had no effect on infection duration or mouse mortality. Mean time until
death was 3.5 days for both treatment and control groups (data not shown).
Thus, although EGCG has trypanocidal activity at supraphysiological
concentrations, the compound did not attenuate virulence in our acute infection
mouse model. EGCG concentrations may not have been sufficiently high in the
mouse bloodstream to affect the parasite, however a much lower intraperitoneal
dose (0.8 mg/kg/day) led to a significant decrease in parasitemia and increased
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survivorship of mice infected with T. cruzi (Güida et al., 2007). Alternatively, it is
possible that the course of infection was too rapid to allow EGCG to exert its
effects. If so, a chronic infection model might be better suited to examine the
efficacy of EGCG as a possible anti-trypanosomiasis therapy.
In summary, we found that EGCG inhibits TbACC activity in lysates, and
this inhibition was correlated with an increase in ACC phosphorylation. This
suggests that EGCG may be a useful tool for studying the effects of
phosphorylation on TbACC activity. We also demonstrated that EGCG kills both
PF and BF parasites in culture. However, EGCG treatment did not affect T. b.
brucei virulence in a mouse model of acute infection, which reduces its promise
as a therapeutic candidate to treat T. brucei infection.

METHODS
Materials, cell lines, and media
Most chemicals and reagents were purchased from Thermo Fisher
Scientific and Sigma, including EGCG (E4143), which was prepared and frozen
in single-use aliquots, either as a 100X stock in dimethyl sulfoxide (DMSO) or in
sterile water for use in mice. EGCG stocks were freshly thawed just before use.
Minimum Essential Medium Eagle and Iscove’s Modified Dulbecco’s Medium,
was from Invitrogen. Serum Plus was from JRH Biosciences. [14C]NaHCO3
(14.9 mCi mmol-1) was from American Radiolabeled Chemicals. Wild-type (WT)
T. b. brucei 427 bloodstream form (BF) and tsetse midgut procyclic form (PF) cell
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lines were a kind gift of Dr. Paul Englund (Johns Hopkins School of Medicine).
BFs were grown at 37°C/5% CO2 in HMI-9 media containing 10% heatinactivated fetal bovine serum (FBS) and 10% Serum Plus (Hirumi and Hirumi,
1989). PFs were grown at 28°C/5% CO2 in SDM-79 media containing 10% heatinactivated FBS and 7.5 µg ml-1 hemin (Brun and Shonenberger, 1979). PF ACCmyc cells are tagged in one genomic locus with a c-terminal fusion to the c-myc
epitope and have been described previously (Vigueira and Paul, 2011). BF ACCmyc cells were generated in this study with the same tagging construct used to
make the PF ACC-myc cell line. ACC-myc cell lines are maintained in the
appropriate growth media supplemented with 2.5 µg ml-1 phleomycin.

Effect of EGCG on T. b. brucei growth
WT BF T. b. brucei were diluted into fresh media containing 0.1-1 µM
EGCG or 1% DMSO as the solvent control and the cell culture densities
measured every 2 days for 6 days by flow cytometry (BD FACScan). Following
each cell count, cultures were diluted to maintain logarithmic phase growth, and
EGCG/DMSO was added to maintain experimental concentrations. Doubling
times were calculated from the growth curves.
To determine EC50 for growth, WT BF and PF T. brucei were diluted into fresh
media containing 5-50 µM EGCG or 1% DMSO as solvent control and cell culture
densities determined after 2 days.
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ACC activity assays
Hypotonic lysates were desalted and TbACC activity was assayed
essentially as described (Vigueira and Paul, 2011). Briefly, ACC activity was
determined by measuring the incorporation of the [14C]CO2 from [14C]NaHCO3
into the acid resistant [14C]malonyl-CoA product, which is quantified by
scintillation counting. To test the effect of EGCG on TbACC activity, 5-100 µM
EGCG or 1% DMSO only (solvent control) was added to the lysates with or
without 1X HALT phosphatase inhibitor cocktail (Thermo Scientific Pierce) just
prior to assaying for TbACC activity.

ACC phosphorylation and blotting
Hypotonic lysates from BF and PF ACC-myc cells were prepared in the
presence of 1X HALT phosphatase inhibitor cocktail. Lysates were supplemented
with 5 mM ATP, divided, with one aliquot treated with 100 µM EGCG and the
other with 1% DMSO as solvent control. Lysates were then incubated at 30˚C for
30 min. under constant mixing (Eppendorf Thermomixer, 500 rpm). ACC-myc
was immunoprecipitated from the lysates using the ProFound c-myc IP/Co-IP kit
(Thermo Scientific Pierce) according to the manufacturer’s instructions and
eluted in 150 mM glycine at pH 2.2 followed by immediate neutralization with 9.5
M Tris-HCl, pH 9.0.
To detect phosphorylated ACC-myc, approximately equal quantities of
immunoprecipitated ACC-myc (~8.8 x 107 cell equivalents/lane for PF and ~1.5 x
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108 cell equivalents/lane for BF) were resolved by SDS-10%PAGE, followed by
gel staining with Pro Diamond Q phosphoprotein gel stain (Invitrogen) according
to the manufacturer’s instructions. Phospho-stained gels were imaged using the
Gel Doc XR Imaging System (BioRad). To detect total ACC, identically loaded
non-stained gels were transferred to nitrocellulose and probed for ACC as
described (Vigueira and Paul, 2011) with streptavidin conjugated to horseradish
peroxidase (SA-HRP), which detects the ACC biotin prosthetic. Densitometric
quantification was performed on gels and appropriately exposed blots (in the
linear range of detection) using Image J software (NIH). Phosphorylated ACCmyc was normalized to the total amount of ACC in the ACC-myc
immunoprecipitates and lysates.

Mouse infection
To test the ability of EGCG to clear a T. b. brucei infection in mice, we
chose a daily dose of 4.13 mg/kg EGCG prepared in sterile H2O and
administered daily by IP injection. This EGCG concentration had been previously
determined not to cause mouse liver damage, though actual serum levels of
EGCG were not determined (Güida et al., 2007). For the EGCG-treated group,
12 week old Swiss mice were pre-treated with EGCG for two days prior to
infection and EGCG treatment was continued throughout the course of infection.
Both the EGCG-treated (n=5) and untreated controls (n=5) were infected with
1x105 BF wild-type 427 parasites as previously described (Bacchi et al., 2009).
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Tail blood samples were examined by microscopy to confirm successful infection,
and time to death (or humane end-point) was determined. All work with animals
was carried out in compliance with a protocol approved by the Clemson
University Institutional Animal Care and Use Committee.
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FIGURES
Figure 3.1 Inhibition of TbACC activity by EGCG. TbACC activity in lysates
of (A) BF and (B) PF trypanosomes was measured in the presence of 5–100 μM
EGCG in the absence (black bars) or presence (grey bars) of HALT phosphatase
inhibitor cocktail. As a negative control, ATP was omitted from the reaction (No
ATP). Values are expressed as a percentage of the DMSO solvent control.
DMSO concentrations were maintained at 1% v/v for all conditions. The mean of
3 independent experiments is shown. Error bars indicate ±SEM. The *
indicates P < 0.01 for the difference between DMSO control and EGCG-treated
conditions (student’s t-test).
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Fig 3.2 EGCG induces phosphorylation of TbACC. BF and PF ACC-myc
lysates were treated with 100 μM EGCG or DMSO as solvent control in the
presence of HALT phosphatase inhibitor cocktail. (A) BF and (B) PF TbACC-myc
immunoprecipitates (∼5 × 108 cell equivalents/lane) were resolved by SDS–
PAGE and stained with Pro Q Diamond phosphoprotein gel stain to detect
phosphorylated ACC (ACC-p; upper panels). Identically loaded gels were blotted
to nitrocellulose and probed for total ACC with SA-HRP (ACC-t; bottom panels).
Representative gels and blots are shown. Unlabeled upper band in panel A is an
unknown phosphorylated contaminant. (C) Densitometric quantification of
phosphorylated ACC from phospho-stained gels normalized to total ACC
detected by SA-HRP blotting. The mean of 3 independent experiments is shown.
Error bars indicate the ±SEM. The * indicates P < 0.05 and **
indicates P < 0.00001 for the difference between DMSO control and EGCGtreated conditions (student’s t-test).
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Fig 3.3 Effect of EGCG on in vitro growth of T. brucei. (A and B) WT BF cells
were diluted back to 1 × 106 cells/ml into fresh media containing 0.1–1 μM EGCG
or DMSO as the solvent control and culture cell densities were monitored for
6 days. (A) Representative growth curve showing cumulative culture densities.
(B) Mean culture doubling times of 3 independent experiments. Error bars show
±SEM. (C) WT BF and (D) WT PF cells were back-diluted into fresh media
containing 5–50 μM EGCG or DMSO control. Culture cell densities were
determined after 48 h. Values are expressed as a percentage of DMSO control.
The mean of 4 independent experiments is shown. Error bars show ±SEM. The *
indicates P < 0.01 for the difference between DMSO and EGCG-treated
conditions (student’s t-test).
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CHAPTER 4
ALLOSTERIC REGULATION OF Trypanosoma brucei ACETYL-COA
CARBOXYLASE

INTRODUCTION
Trypanosoma brucei is a protozoan extracellular parasite that is
introduced into the bloodstream of a mammalian host by its tsetse fly vector
during a blood meal. From the mammalian bloodstream, the parasite crosses the
blood brain barrier and passes into the central nervous system. T. brucei causes
a fatal disease in humans known as African sleeping sickness and a wasting
disease in livestock known as Nagana. If not treated, this disease is nearly 100%
fatal. Currently available drugs are highly toxic and resistance is a growing
problem. Hence, there is a need to find novel therapeutics (Jacobs et al., 2011).
Throughout its life cycle, the parasite experiences different nutrient levels
in the microenvironments of its hosts. In these microenvironments, the parasite
undergoes physiological changes in order to adapt to its host. For example, T.
brucei bloodstream forms (BFs) upregulate genes such as pyruvate kinase 1 and
hexokinase 1, while tsetse midgut procyclic forms (PFs) upregulate
phosphoglycerate kinase and the cytochromes (Jenson et al., 2009).
Both BF and PF T. brucei require fatty acids (FAs) and can readily take
FAs from their hosts (Coppens et al., 1995; Green et al., 2003)., Under
conditions of limited environmental FAs, however T. brucei can also synthesize
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FAs de novo (Dixon et al., 1971; Morita et al., 2000). The first committed step in
FA synthesis is catalyzed by acetyl-CoA carboxylase (ACC), which converts
acetyl-CoA to malonyl-CoA, the two carbon donor for the ER-localized FA
synthesis pathway (Lee et al., 2006). However, FA synthesis is an energy
intensive biosynthetic pathway. For example, the parasite would need to expend
6 ATP and 12 NADH/NADPH reducing equivalents to synthesize a 16-carbon
FA, while uptake and activation of the same FA from the host might require only
1 ATP. As FA synthesis is such an energy-utilizing process, it likely to be
important for T. brucei to regulate the balance between FA synthesis and uptake.
Because it catalyzes the first committed step in FA synthesis, ACC plays a
central role in lipid metabolism in other organisms and has been shown to be
controlled by multiple regulatory mechanisms (Lane et al., 1974; Moule et al.,
1992; Anderson et al., 1998; Andre et al., 2012). Most ACCs are subject to
allosteric regulation by metabolites upstream (feed-forward signals) and
regulation by downstream products (feedback signals) (Andre et al., 2012). ACC
is also known to undergo conformational changes that modulate its activity
(Vagelos et al., 1963; Lane et al., 1974). Metabolites such as citrate, glutamate,
and other dicarboxylic acids activate ACC (Vagelos et al., 1963; Lane et al.,
1974), while fatty acyl-CoAs function as negative regulators (Moule et al., 1992;
Anderson et al., 1998).
In this chapter, I examined allosteric regulation of TbACC and the effect of
different modulators on TbACC activity: adenine nucleotides such as cAMP and
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AMP; metabolic intermediates such as pyruvate, citrate, glutamate, and acetate;
and fatty acyl-CoAs. I also assessed the oligomeric state of TbACC under normal
lipid growth conditions. I found that TbACC activity was reduced when treated
with increasing concentration of AMPK. TbACC showed increased activity in the
presence of metabolic intermediates, with highest activity when treated with
citrate and moderate increase when treated with acetate and glutamate. TbACC
was inhibited by fatty acyl-CoA in a chain-length dependent manner. I also
demonstrated that TbACC potentially, might form oligomers.

RESULTS
AMP decreased and cAMP increased TbACC activity
AMP-activated protein kinase (AMPK) and protein kinase A (PKA) were both
previously known to affect ACC in other organisms (Boone et al., 1999; Park et
al., 2002), and homologs to both kinases were present in T. brucei (Clemmens et
al., 2009; Kramer, 2005). As AMPK and PKA were responsive to AMP and
cAMP, respectively, we first examined the effect of these adenine nucleotides on
TbACC activity. PF WT lysates were assayed for ACC activity as described
previously (Vigueira and Paul, 2011) in the presence of a 12.5–100 µM AMP and
cAMP (see Table 4.1). TbACC showed a decrease in activity with increasing
concentrations of AMP (~40% reduction at the highest concentration tested (100
µM)) (Fig. 4.1). In contrast, cAMP treatment increased TbACC activity, and this
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increase was only significant at the highest concentration of cAMP tested (100
µM) (Fig 4.1).

Figure 4.1: AMP and cAMP affected PF TbACC activity. Hypotonic lysates prepared from WT
PFs were treated with 12.5–100 µM AMP (black bars) and cAMP (grey bars) and assayed for
TbACC activity. As a negative control, ATP was omitted from the reaction (No ATP). Values are
expressed as a percentage of the untreated control. The mean ± SEM of 3 independent
experiments is shown. ** P < 0.01 for the difference between control and treatment (Student’s tTest).

Citrate increased TbACC activity
Next we examined the effect of intermediate metabolites on TbACC activity. WT
PF lysates were treated with citrate, pyruvate, glutamate, or acetate, and
assayed for TbACC activity. Citrate caused a dose-dependent increase in
TbACC activity (Fig. 4.2A), while glutamate and acetate had a small but
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significant positive effect on TbACC activity (Fig. 4.2B). Pyruvate treatment had
no apparent effect on TbACC activity except at 10 mM (Fig. 4.2A).

A.

B.

Figure 4.2: Citrate increased TbACC activity. WT PF hypotonic lysates were treated with (A.)
12.5 µM–10 mM citrate (black bars) and pyruvate (grey bars) or (B.) 0.5–10 mM acetate (black
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bars) and glutamate (grey bars) and assayed for TbACC activity. As a negative control, ATP was
omitted from the reaction (No ATP). Values are expressed as a percentage of untreated control.
The mean ± SEM of 3 independent experiments is shown. * P < 0.05 and ** P < 0.01 for
difference between control and treated conditions (Student’s t-test).

Fatty acyl-CoAs inhibited TbACC activity in a chain-length dependent
manner Mammalian ACCs are subject to feedback inhibition by the product of
FA synthesis, palmitoyl-CoA. Thus, we examined whether TbACC was also
inhibited by fatty acyl-CoAs and if there was a dependence on acyl-chain length.
WT PF lysates were treated with fatty acyl-CoAs 12–18 carbons in length and
assayed for TbACC activity. TbACC was inhibited by fatty acyl-CoAs, with the
strongest inhibition observed with C16 palmitoyl-CoA and C18 stearoyl-CoA
(EC50s of 12.6 µM and 12.5 µM, respectively) (Fig. 4.3). TbACC was less
sensitive to C14 myristoyl-CoA (EC50=40.6 µM) and largely refractory to C12
lauroyl-CoA.
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Figure 4.3: Fatty acyl-CoAs inhibit PF TbACC activity in lysates. WT PF hypotonic lysates
were treated with 10–50 µM fatty acyl-CoAs and assayed for TbACC activity. As a negative
control, ATP was omitted from the reaction (No ATP). Values are expressed as a percentage of
the untreated control. The mean ± SEM of 3 independent experiments is shown. * P < 0.05 and
**P < 0.01 for the difference between control and treated conditions (Student’s t-Test).

TbACC exists in oligomers
Mammalian and avian ACCs form polymers which suggests that TbACC also
might form higher order structures. Thus, we determined the oligomeric structure
of TbACC using size exclusion chromatography. Hypotonic lysates prepared
from WT PFs grown in normal lipid media were fractionated on an S300
sephacryl column equilibrated in BC buffer. Column fractions were blotted for
total ACC using SA-HRP (Fig. 4.4C). TbACC was found in complexes estimated
to range between 400-1000 kDa when compared to a standard curve generated
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from molecular weight standards sized on the same column under the same
buffer conditions (Fig. 4.4A and B). Given a predicted molecular weight of 243 kD
for TbACC, the gel filtration data suggests that TbACC might exist as a mixture of
oligomers, which correspond in size to dimers, trimers, and tetramers of TbACC.
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A.

B.

C.

Fig 4.4: TbACC exists in oligomers. PF WT hypotonic lysates were resolved by Sephacryl S300 size exclusion chromatography and TbACC detected in column fractions by SA-HRP blotting.
(A.) Abs280 nm of indicated protein standards (B.) Standard curve of the log molecular weights
vs. distribution coefficient (Kav). (C.) SA-HRP blotting of column fractions for total TbACC.
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DISCUSSION
We hypothesized that TbACC would be subject to allosteric regulation, as
this is true of ACC in all other organisms studied to date (Vagelos et al., 1963;
Lane et al., 1974). We examined the effect of three classes of potential allosteric
regulators on TbACC activity in WT PF hypotonic lysates. We first examined the
effect of adenine nucleotides (AMP and cAMP) for their effect on TbACC activity.
TbACC activity was only mildly stimulated by cAMP. In contrast, TbACC was
significantly inhibited by AMP in a dose-dependent manner. It is unclear whether
this inhibition of TbACC by AMP is due to a direct or indirect effect on TbACC.
AMP could be competing for ATP-binding in the active site, though the assay
conditions have a 10-fold higher concentration of ATP (0.5 mM). AMP could also
be binding to a second regulatory site of TbACC. Finally, AMP could be acting
indirectly through the activation of AMPK, which is known to phosphorylate and
inhibit ACC in other organisms. This mode of action is supported by our studies
in Ch. 3 that showed the AMPK activator EGCG inhibited PF TbACC with
increasing concentration in a phosphorylation-dependent manner.
As metabolic intermediates reflect the nutritional state of an organism, we
also examined the effect of intermediate metabolites (acetate, citrate, glutamate
and pyruvate) on TbACC activity. We found that pyruvate did have a stimulatory
effect on TbACC activity, though only at the highest concentration tested (10
mM). To our knowledge, this is the first reported stimulation of ACC by pyruvate.
In most cells, including T. brucei, pyruvate is the major metabolic source of
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acetyl-CoA for FA synthesis. Pyruvate is converted to acetyl-CoA by pyruvate
dehydrogenase complex (PDH) followed by the transport of acetate back to the
cytosol via the citrate/malate shuttle (Hatzivassiliou et al., 2005). There is some
evidence for this pathway operating in T. brucei (Riviere et al., 2009). These
experiments elucidated an alternate pathway in T. brucei involving the
conversion of pyruvate to acetyl-CoA within the mitochondrion by PDH and
subsequent conversion to acetate by an acetate:succinate-CoA transferase,
followed by transport of acetate into the cytosol by an unknown transporter where
an acetyl-CoA synthetase rapidly re-esterifies it to acetyl-CoA (Rivière et al.,
2009). Thus, pyruvate may serve as feed-forward signal reflecting high nutrient
status in the parasite and the need to synthesize FAs and the precursors needed
to synthesize lipids (Fig. 4.5).
We found that citrate had the most significant effect of the metabolites
tested, stimulating TbACC activity in a nearly dose-dependent manner. The
existence of a citrate-dependent alternate pathway for acetyl-CoA production
from citrate is already known in T. brucei, which might explain why citrate had a
significant effect on TbACC activity (Rivière et al., 2009) (Fig. 4.5). This citrate
stimulation of TbACC is also in accordance with mammalian and avian ACCs,
which are known to be activated by citrate and glutamate (Beatty and Lane et al.,
1983). In addition, citrate and glutamate were shown to induce polymerization of
ACC thereby increasing its activity (Beatty and Lane et al.,
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Fig 4.5: T. brucei metabolic pathways showing different allosteric regulators and their effect on TbACC

1983; Cesquini et al., 2008). TbACC was only mildly stimulated by glutamate,
suggesting it may not be as sensitive to feed-forward signals of amino acid
metabolism. A key enzyme in glutamate metabolism is glutamate dehydrogenase
(Newsholme et al., 2003). However, earlier studies in T. brucei showed that
knockout of glutamate dehydrogenase had no effect on the parasite (Estevez et
al., 1999). Perhaps other amino acids, such as proline or threonine, might be
more relevant to TbACC regulation in T. brucei, as proline metabolism is already
known to be important in PFs (Coustou et al., 2008; Bringaud et al., 2012) and
threonine can serve as a source of acetyl-CoA for FA synthesis (Linstead et al.,
1974). Finally, acetate also showed a mildly stimulating effect on TbACC, which
might be due to activation of AMP-forming acetyl-CoA synthetase (Fig. 4.5).
However, the concomitant generation of AMP, which we have already shown
inhibits ACC, may explain the mild effect of acetate.
Fatty acyl-CoAs are the final products of FA synthesis and thus, we
examined their effect on TbACC activity. TbACC exhibited an acyl chain-length
dependent inhibition of activity, with longer chain lengths such as palmitoyl-CoA
(C16) and stearoyl-CoA (C18) showing more robust inhibition, followed by
myristoyl-CoA (C14). Lauroyl-CoA (C12) had no effect on TbACC activity. This
chain-length specificity of fatty acyl-CoA action might be explained by the FA
requirements of PFs. PFs express procyclin as their surface coat protein and are
attached to the plasma membrane by a GPI-anchor that contains palmitate (C16)
and stearate (C18) FAs (Butikofer et al., 1997). Hence, in PFs there is a demand
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for longer chain FAs and thus FA synthesis is not affected by the shorter FAs.
Mammalian hepatic ACC is known to bind reversibly to palmitoyl-CoA resulting in
inhibition of the enzyme (Ogiwara et al., 2008). To our knowledge the chainlength specificity of this inhibition in mammalian ACCs has not been explored.
Mammalian and avian ACCs polymerize in response to both allosteric
regulators and dephosphorylation (Vagelos et al., 1963; Lane et al., 1974). In
yeast, an ACC mutant was shown to form planar arrays (Schneiter et al., 1996),
suggesting ACC may also polymerize in yeast. Finally, immunofluorescence
microscopy studies of TbACC demonstrated that the enzyme is localized to
numerous cytoplasmic puncta (Vigueira and Paul, 2011). Based on these
observations, we examined the oligomeric state of TbACC by size exclusion
chromatography. In PFs, TbACC was found to exist in complexes that migrated
with a molecular weight range of 400-900 KDa, consistent with a mixture of
dimers, trimers, and tetramers. Detection of TbACC oligomers suggested the
possibility that TbACC might be regulated at the level of quaternary structure in
addition to regulation by phosphorylation and at the level of protein expression.
However, the fractionation was performed with lysate rather than purified protein,
thus we cannot rule out the role of other proteins interacting with TbACC
(Magnard et al., 2002). We also cannot rule out the possibility that TbACC
formed aggregates, but sub-cellular fractionation of TbACC performed under
similar conditions showed that TbACC behaved as a soluble cytosolic protein
and no indication of aggregation was observed (Vigueira et al., 2011). The
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TbACC oligomers isolated in our studies were too small to consist of the puncta
seen by microscopy. A possible explanation for this disparity may be that the
TbACC oligomers are unstable in lysates and hence, the higher-order polymers
break into the smaller protomers we observed by gel filtration. In mammals, ACC
binds to a 22 kDa cytosolic protein, MIG12, which stabilizes the ACC polymer
(Kim et al., 2010). No MIG12 homolog was found in the T. brucei genome, which
might also explain the relative instability of the larger TbACC structures.
In summary, I have shown that TbACC activity is inhibited by AMP and
long-chain fatty acyl-CoAs and stimulated by citrate and to a lesser extent,
acetate and glutamate indicating a degree of metabolic control of TbACC in
response to the nutritional state of the cell. The extent to which this regulation
involves direct binding to TbACC remains to be determined. Finally, TbACC
might exist as a mixture of oligomers in PFs grown in normal media. However
this will need to be confirmed with purified protein and sedimentation studies. If
TbACC oligomers are confirmed, it will be interesting to determine if the TbACC
oligomeric state is affected by growth in high or lipid media or in response to the
effectors such as AMP and glutamate, which we already demonstrated alter
TbACC activity in lysates.
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METHODS
Effect of allosteric regulators on TbACC activity
WT PFs were grown to mid-logarithmic stage. Hypotonic lysates were
prepared from 5 x 108 cells and chromatographed through a Sephadex G50
column to remove endogenous substrates. The resulting lysates were treated
with different concentrations of allosteric regulators (Table 4.1) and TbACC
activity assayed essentially as described (Vigueira and Paul, 2011), except the
final acetyl-CoA concentration was 2.5 mM. Values were normalized to the “No
ATP” control and expressed as a percentage of untreated lysate. Significance of
differences between treatment and control were determined using the Student’s
t- Test.

137

Table 4.1 Tested concentrations of potential allosteric regulators
Class

Name

Concentrations

cAMP

0, 12.5, 25, 50, 100 µM

AMP

0, 12.5, 25, 50, 100 µM

Pyruvate

0,12.5, 25, 50, 100 µM

Adenine nucleotides

Metabolic intermediates

0.5, 1, 5, 10 mM
Citrate

0,12.5, 25, 50, 100 µM
0.5, 1, 5, 10 mM

Acetate

0, 0.5, 1, 5, 10 mM

Glutamate

0, 0.5, 1, 5, 10 mM

Lauroyl-CoA

0, 10, 20, 30, 40, 50 µM

Myristoyl-CoA

0, 10, 20, 30, 40, 50 µM

Palmitoyl-CoA

0, 10, 20, 30, 40, 50 µM

Stearoyl-CoA

0, 10, 20, 30, 40, 50 µM

Fatty acyl-CoAs

Sizing of TbACC oligomers
PF WT hypotonic lysates were prepared from cells grown in normal lipid
conditions. Size exclusion chromatography was performed using a Sephacryl S300 column and the AKTA Prime Plus chromatography and purification system
(GE Healthcare) for sample injection, separation, and fraction collection. The
column was equilibrated in BC Buffer (50 mM Tris-Cl pH 8.0, 5 mM MgCl2, 5 mM
DTT) and run in the same buffer. Samples were injected in a volume of 800 µl,
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separated at a flow rate of 0.5 ml min-1, and 1 ml fractions were collected at room
temperature. The column fractions were resolved by SDS-PAGE and total ACC
detected by SA-HRP blotting. Calibration of the column was performed using a
standard curve generated by the separation of blue dextran (void volume) and
the following protein standards: Thyroglobulin (660 KDa), Ferritin (440 KDa),
Aldolase (161 KDa) and Conalbumin (76 KDa). Protein peaks were monitored
using the UV detector at 280 nm.
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CHAPTER 5
CONCLUDING REMARKS

Trypanosoma brucei is a protozoan extracellular parasite that is
transmitted by infected tsetse flies. T. brucei affects sub-Saharan Africa, where it
causes human African trypanosomiasis (HAT). T. brucei also causes a wasting
disease in livestock called Nagana, which makes agriculture very difficult and has
caused this region of Africa to be nicknamed the “green desert”, owing to the
tremendous economic impact T. brucei has had on the people living in this
poverty stricken continent (FAO, 2002). The survival of T. brucei within its hosts
is very much dependent upon the ability of the parasite to evade the immune
system of its host. The ability of T. brucei to evade its host immune system is in
turn dependent upon the expression of surface coat proteins. The requirement of
the T. brucei surface coat proteins for fatty acids (FAs) as part of their membrane
anchor creates a high demand for FAs in this parasite.
T. brucei readily acquires FAs from its hosts. When the host supply is
limited, T. brucei can synthesize its own FAs using its FA synthesis pathways.
Uptake of lipids requires much less energy than FA synthesis, yet aspects of the
biology of this parasite involving the regulation of FA synthesis, the sensing of
environmental lipids, and the mechanism of regulation, has never been studied in
T. brucei. Environmental regulation of FA synthesis would allow preferential use
of host FA resources, and would only turn on FA synthesis when the supply of
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the host is insufficient. The research I presented in this doctoral dissertation has
added to our growing knowledge about lipid metabolism in T. brucei.
A key substrate for FA synthesis is malonyl-CoA, which is synthesized
from acetyl-CoA by acetyl-CoA carboxylase (ACC). Because ACC likely serves
as one control point for regulating FA synthesis, I studied the regulation of T.
brucei ACC (TbACC) in response to environmental lipids. I demonstrated that
procyclic form (PF) T. brucei regulated TbACC at the protein, activity, and posttranslational levels in response to environmental lipids. The green tea catechin,
epigallocatechin gallate (EGCG), induced ACC phosphorylation and reduced
TbACC activity (Vigueira et al., 2012). However, unlike in PFs, no change in
TbACC RNA or protein levels, activity, or phosphorylation was observed in BFs
in response to environmental lipids.
Our current model is that in PFs, TbACC was regulated by environmental
lipids, where it played a role in resource management: the parasite only
synthesized FAs when host lipids are insufficient. We also demonstrated that at
least in PFs, TbACC was both positively and negatively regulated by a variety of
metabolites. For example, citrate increased TbACC activity, whereas AMP and
long chain fatty acyl-CoAs inhibited TbACC activity. In contrast, BF TbACC was
not regulated by environmental lipids. Instead, we propose that BF TbACC was
always active to support immune evasion strategies, such as upregulation of
endocytosis, that require extensive membrane turnover.
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As Russell L. Ackoff rightly said, “The extensive literature addressed to the
definition or characterization of science is filled with inconsistent points of view
and demonstrates that an adequate definition is not easy to attain. Part of the
difficulty arises from the fact that the meaning of science is not fixed, but is
dynamic. As science has evolved, so has its meaning. It takes on a new meaning
and significance with successive ages.” My dissertation work established
important background on the regulation of T. brucei FA synthesis, while raising
many questions. I hope my dissertation stimulates future work aimed at
understanding various aspects of T. brucei lipid metabolism. Key questions that
can be addressed in the future are as follows:

What are the phosphorylation sites in TbACC and how does each site
contribute to the regulation of TbACC?
We know that ACC lacks canonical phosphorylation sites, but a recent
phosphoproteomics study identified three serines in TbACC that were
phosphorylated (Urbaniak et al., 2013). It will be interesting to validate these
phosphorylation sites and determine if there are additional phosphorylation sites.
This information will provide insight into how phosphorylation of TbACC might
alter the activity of the enzyme. Finally it will be useful to determine how
phosphorylation at each site is regulated and the contribution of each site to
overall TbACC activity.
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What is/are the TbACC kinases?
My research provided indirect evidence for multiple kinases (PKA, PKC,
PKB, and AMPK) that might potentially phosphorylate TbACC. However, no
direct TbACC kinase has been identified. Identifying the TbACC kinase(s) will not
only help determine the signaling cascade(s) regulating TbACC and FA
synthesis, but also can point the way towards the development of new
therapeutics. Inducers of these kinases could trigger TbACC phosphorylation,
making it inactive. Inactivating TbACC might have therapeutic potential, as we
know from earlier studies in our lab that ACC was essential to establish infection
and was required for full virulence in mice (Vigueira and Paul, 2011).

How is T. brucei sensing environmental lipids?
We observed stage-specific differences in TbACC regulation in the
presence of environmental lipids. All environmental regulation was observed in
PFs, whereas in BFs, ACC showed constitutive activity. It will be interesting to
know how the parasites “read” the environmental lipids and what proteins are
involved. TbACC could potentially sense environmental lipids directly through
binding of fatty acyl-CoAs. But the changes in TbACC phosphorylation in
response to environmental lipids also suggested that a signal transduction
pathway may be involved. Finally, it will be useful to determine the underlying
mechanisms governing the differences in how each life cycle stage senses
environmental lipids.
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Is TbACC regulated by other mechanisms, such as acetylation or
ubiquitination?
Acetylation of lysine residues has been demonstrated in various metabolic
enzymes in human liver (Zhao et al., 2010; Wang et al., 2010). Key enzymes in
FA metabolism, such as acetyl-CoA synthetases, are also acetylated (Starai et
al., 2002). It will be interesting to know if TbACC is acetylated and what effect
acetylation has on TbACC. Perhaps acetylation plays a role in making the
decision between FA synthesis and uptake. Acetylation could alter ACC activity
by promoting substrate binding, inhibiting substrate binding, or stimulating
selective degradation of TbACC by ubiquitination (Xiong et al., 2011).
Although no change in TbACC mRNA levels were observed, PFs did show
changes in TbACC protein levels in response to changes in environmental lipids.
This regulation could occur through regulated ubiquitination and degradation of
TbACC protein. It will be interesting to examine if high lipid conditions activate a
ubiquitin ligase that ubiquitylates TbACC leading to its selective degradation.
The work presented in this dissertation contributed new knowledge about
FA synthesis and its regulation in the protozoan parasite T. brucei. I hope my
work will also shed light on the pathobiology of other related organisms, that
possess similar pathways to regulate FA synthesis. An increased understanding
of the role of FA synthesis and regulation in host adaptation and pathogenesis
opens the door not only to the treatment of HAT, but also may help in the
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development of therapeutic approaches against other trypanosomatids such as
Trypanosoma cruzi, which causes Chagas disease, and Leishmania, which
causes leishmaniasis.

150

REFERENCES
FAO. 2002. Fighting tsetse -- a scourge to African farmers. FAO United Nations
Newsroom, www. Fao.org/enlish/newsroom/news/2002/4620_en.html.
Accessed 7/26/2013.
Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC. 2002. Sir2dependent activation of acetyl-CoA synthetase by deacetylation of active
lysine. Science 298:2390-2.
Urbaniak MD, Martin DM, Ferguson MA. 2013. Global quantitative SILAC
phosphoproteomics reveals differential phosphorylation is widespread
between the procyclic and bloodstream form lifecycle stages of
Trypanosoma brucei. J Proteome Res 12:2233-44.
Vigueira PA, Ray SS, Martin BA, Ligon MM, Paul KS. 2012. Effects of the green
tea catechin (−)-epigallocatechin gallate on Trypanosoma brucei. Int J for
Par: Drugs and Drug Resistance 2:225-9.
Wang Q, Zhang Y, Yang C, Xiong H, Lin Y Yao J, Li H, Xie L, Zhao W, Yao Y,
Ning Z, Zeng R, Xiong Y, Guan KL, Zhao S, Zhao GP. 2010. Acetylation
of metabolic enzymes coordinates carbon source utilization and metabolic
flux. Science 327:1004-7.
Xiong Y, Guan KL. 2012. Mechanistic insights into the regulation of metabolic
enzymes by acetylation. J Cell Biol 198:155-64.

151

Zhao S, Xu W, Jiang W, Yu W, Lin Y, et al. 2010. Regulation of cellular
metabolism by protein lysine acetylation. Science 327:1000-4.

152

